Exhibit 99.2
KPMG Audit | Telephone: | +33 (0)1 55 68 68 68 | ||||
Tour EQHO | Telefax: | +33 (0)1 55 68 73 00 | ||||
2 Avenue Gambetta | Internet: | www.kpmg.fr | ||||
CS 60055 92066 Paris la Défense Cedex | ||||||
France |
HERA S.A.S.
Statutory auditor’s report on the consolidated
financial statements as of and for the years ended
December 31, 2020 and 2021
Years ended December 31, 2020 and 2021
HERA S.A.S.
200, avenue de Paris – 92320 Chtillon
KPMG S.A a French limited liability entity and a member firm of the KPMG Network of independent member firms affiliated with KPMG International Limited, a private Englsh company limited by guarantee | Société anonyme d’expertise comptable et de commissariat aux comptes à directoire et conseil de surveillance. Inscrite au Tableau de l’Ordre à Paris sous le n° 14-30080101 et à la Compagnie Régionale des Commissaires aux Comptes de Versailles.et du Centre | Headquarters: KPMG S.A. Tour Eqho 2 avenue Gambetta 92066 Paris la Défense Cedex Capital: 5 497 100 €. Code APE 6920Z 775 726 417 R.C.S. Nanterre TVA Union Européenne FR 77 775 726 417 |
KPMG Audit | Telephone: | +33 (0)1 55 68 68 68 | ||||
Tour EQHO | Telefax: | +33 (0)1 55 68 73 00 | ||||
2 Avenue Gambetta | Internet: | www.kpmg.fr | ||||
CS 60055 92066 Paris la Défense Cedex | ||||||
France |
HERA S.A.S
Registered office: 200, avenue de Paris – 92320 Chatillon
Statutory auditor’s report on the consolidated financial statements as of and for the years ended December 31, 2020 and 2021
To the Chairman of HERA S.A.S.;
In our capacity as Statutory Auditor of HERA S.A.S. and in compliance with your request in the context of the proposed acquisition of HERA S.A. by Perrigo Company Plc, we have audited the accompanying consolidated financial statements of HERA S.A.S. as of and for the years ended December 31, 2020 and 2021.
Due to the global crisis related to the Covid-19 pandemic, the consolidated financial statements have been prepared and audited under specific conditions. Indeed, this crisis and the exceptional measures taken in the context of the state of sanitary emergency have had numerous consequences for companies, particularly on their operations and their financing, and have led to greater uncertainties on their future prospects. Those measures, such as travel restrictions and remote working, have also had an impact on the companies’ internal organisation and the performance of the audits.
The Chairman of HERA S.A.S. is responsible for the preparation and fair presentation of these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
We conducted our audit in accordance with professional standards applicable in France and the professional doctrine of the French national auditing body (Compagnie nationale des commissaires aux comptes) related to this engagement; these standards require that we plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement. An audit involves performing procedures, on a test basis or by other means of selection, to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting policies used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position and assets and liabilities of HERA S.A.S. as of December 31, 2020 and 2021 and the results of its operations for the years then ended in accordance with International Financial Reporting Standards (“IFRS”) as adopted in the European Union and in accordance with IFRS as issued by the International Accounting Standards Board.
KPMG S.A a French limited liability entity and a member firm of the KPMG Network of independent member firms affiliated with KPMG International Limited, a private Englsh company limited by guarantee | Société anonyme d’expertise comptable et de commissariat aux comptes à directoire et conseil de surveillance. Inscrite au Tableau de l’Ordre à Paris sous le n° 14-30080101 et à la Compagnie Régionale des Commissaires aux Comptes de Versailles.et du Centre | Headquarters: KPMG S.A. Tour Eqho 2 avenue Gambetta 92066 Paris la Défense Cedex Capital : 5 497 100 €. Code APE 6920Z 775 726 417 R.C.S. Nanterre TVA Union Européenne FR 77 775 726 417 |
HERA S.A.S.
Statutory auditor’s report on the consolidated financial statements
as of and for the years ended December 31, 2020 and 2021
This report shall be governed by, and construed in accordance with French law. The Courts of France shall have exclusive jurisdiction in relation to any claim, dispute or difference concerning the engagement letter or this report, and any matter arising from them. Each party irrevocably waives any right it may have to object to an action being brought in any of those Courts, to claim that the action has been brought in an inconvenient forum or to claim that those Courts do not have jurisdiction.
Paris la Défense March 23, 2022
KPMG Audit
A division of KPMG S.A.
/s/ Catherine Porta
Catherine Porta
Partner
3
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2021 and 2020
STATEMENT OF FINANCIAL POSITION | 4 | |||||
STATEMENT OF PROFIT AND LOSS | 5 | |||||
CONSOLIDATED STATEMENT OF CASH FLOWS | 6 | |||||
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY | 7 | |||||
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS | 8 | |||||
1 | ACCOUNTING PRINCIPLES AND METHODS | 8 | ||||
1.1 | Reporting Entity | 8 | ||||
1.2 | Accounting principles | 8 | ||||
1.2.1 | Statement of compliance and accounting principles | 8 | ||||
1.2.2 | Basis of measurement and presentation | 9 | ||||
1.2.3 | Functional and reporting currency | 9 | ||||
1.2.4 | Conversion of foreign currency transactions | 9 | ||||
1.2.5 | Translation of financial statements of foreign subsidiaries whose functional currency is not the euro | 9 | ||||
1.2.6 | Use of Judgments and Estimates | 10 | ||||
1.3 | Main accounting principles | 10 | ||||
1.3.1 | Consolidation method | 10 | ||||
1.3.2 | Business combinations | 10 | ||||
1.3.3 | Development costs | 11 | ||||
1.3.4 | Other intangible assets | 11 | ||||
1.3.5 | Property, plant and equipment | 12 | ||||
1.3.6 | Financial assets and liabilities | 12 | ||||
1.3.7 | Inventories and work in progress | 15 | ||||
1.3.8 | Employee benefits | 15 | ||||
1.3.9 | Share-based payments | 16 | ||||
1.3.10 | Provisions | 16 | ||||
1.3.11 | Revenue from ordinary activities | 17 | ||||
1.3.11.1 | Turnover | 17 | ||||
1.3.11.2 | Other income from operations | 17 | ||||
1.3.12 | Research Tax Credit | 17 | ||||
1.3.13 | Cost of sales and other operating expenses | 17 | ||||
1.3.14 | Non-current income and expenses | 17 | ||||
1.3.15 | Lease agreements | 18 | ||||
1.3.16 | Financial income and expenses | 18 | ||||
1.3.17 | Income tax | 18 | ||||
1.3.18 | Earnings per share | 19 | ||||
1.3.19 | Impairment testing of non-financial assets | 19 | ||||
1.4 | Determining fair value | 19 | ||||
1.5 | Significant changes in accounting policies | 20 | ||||
1.6 | Significant events of the fiscal year period | 20 | ||||
1.6.1 | Change of scope | 20 | ||||
1.6.2 | COVID-19 | 21 | ||||
1.6.3 | Buyback offer from PERRIGO | 22 | ||||
1.6.4 | Ongoing legal actions | 22 | ||||
1.6.5 | Other Information | 23 |
2
2 | NOTES TO THE STATEMENT OF FINANCIAL POSITION | 24 | ||||
2.1 | Goodwill | 24 | ||||
2.2 | Intangible assets | 25 | ||||
2.3 | Property, plant and equipment | 26 | ||||
2.4 | Rights of Use associated with Leases | 27 | ||||
2.5 | Current and non-current financial assets | 28 | ||||
2.6 | Inventories | 28 | ||||
2.7 | Trade and other receivables | 29 | ||||
2.8 | Other receivables | 30 | ||||
2.9 | Cash and cash equivalents | 31 | ||||
2.10 | Share capital | 31 | ||||
2.10.1 | Share-based payments - Stock options and free shares | 32 | ||||
2.10.2 | Non-controlling interests | 32 | ||||
2.11 | Provisions for employee benefits | 33 | ||||
2.12 | Provisions | 34 | ||||
2.12.1 | Provisions for tax liabilities | 34 | ||||
2.13 | Borrowings and financial debts | 35 | ||||
2.13.1 | Changes in financial liabilities | 36 | ||||
2.14 | Lease liabilities | 37 | ||||
2.15 | Other debts | 37 | ||||
2.16 | Deferred income | 38 | ||||
2.17 | Fair value table | 39 | ||||
3 | NOTES TO THE STATEMENT OF COMPREHENSIVE INCOME | 39 | ||||
3.1 | Revenue from ordinary activities | 39 | ||||
3.2 | Operating expenses | 40 | ||||
3.2.1 | Staff costs | 40 | ||||
3.2.2 | Headcount | 41 | ||||
3.3 | Other operating income and expenses | 41 | ||||
3.4 | Other non-current income and expenses | 42 | ||||
3.5 | Financial result | 43 | ||||
3.6 | Income tax | 43 | ||||
3.6.1 | Breakdown of tax expense | 43 | ||||
3.6.2 | Reconciliation between actual and notional tax | 44 | ||||
3.6.3 | Breakdown of deferred tax assets and liabilities | 44 | ||||
3.7 | Earnings per share | 45 | ||||
3.7.1 | Basic earnings per share | 45 | ||||
3.7.2 | Diluted earnings per share | 45 | ||||
4 | RELATED PARTIES | 45 | ||||
5 | LITIGATION | 46 | ||||
6 | OFF-BALANCE SHEET COMMITMENTS | 46 | ||||
7 | FINANCIAL RISK MANAGEMENT | 47 | ||||
8 | SUBSEQUENT EVENTS | 47 | ||||
9 | AUDITORS’ FEES | 48 |
3
STATEMENT OF FINANCIAL POSITION
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||||
Assets | ||||||||||
Goodwill | Note 2.1 | 529 585 | 529 585 | |||||||
Intangible assets | Note 2.2 | 514 489 | 505 893 | |||||||
Tangible assets | Note 2.3 | 3 261 | 3 427 | |||||||
Usage rights under leasing contracts | Note 2.4 | 8 654 | 9 873 | |||||||
Financial assets - Non-current portion | Note 2.5 | 773 | 575 | |||||||
Derivative asset instruments - Non-current portion | — | 10 | ||||||||
Deferred taxes - Assets | Note 3.6.3 | 30 618 | 34 577 | |||||||
|
|
|
| |||||||
Non-current assets | 1 087 381 | 1 083 940 | ||||||||
|
|
|
| |||||||
Stocks and work in progress | Note 2.6 | 22 726 | 31 543 | |||||||
Trade and other receivables | Note 2.7 | 53 599 | 48 423 | |||||||
Current tax assets | Note 2.8 | 10 205 | 6 115 | |||||||
Other receivables | Note 2.8 | 11 108 | 13 544 | |||||||
Prepayments | 2 622 | 2 833 | ||||||||
Financial assets - Current portion | 9 | 9 | ||||||||
Derivative asset instruments - Current portion | 63 | 259 | ||||||||
Cash and cash equivalents | Note 2.9 | 40 575 | 18 163 | |||||||
|
|
|
| |||||||
Current assets | 140 907 | 120 888 | ||||||||
|
|
|
| |||||||
TOTAL ASSETS | 1 228 288 | 1 204 827 | ||||||||
|
|
|
| |||||||
Equity | ||||||||||
Share capital | Note 2.10 | 35 862 | 35 862 | |||||||
Share premium | 319 897 | 319 897 | ||||||||
Consolidated reserves - Group share | -171 588 | -145 631 | ||||||||
Profit or loss for the financial year - Group share | -3 166 | -27 241 | ||||||||
|
|
|
| |||||||
Equity - Group share | 181 005 | 182 888 | ||||||||
Non-controlling interests | 107 | 29 | ||||||||
|
|
|
| |||||||
Equity | 181 112 | 182 917 | ||||||||
|
|
|
| |||||||
Liabilities | ||||||||||
Provisions for employee benefits | Note 2.11 | 2 441 | 2 266 | |||||||
Borrowings and financial debts - Non-current portion | Note 2.13 | 842 692 | 815 415 | |||||||
Leasing debts - Non-current portion | Note 2.14 | 7 359 | 8 759 | |||||||
Deferred income - Non-current portion | Note 2.16 | 666 | 625 | |||||||
Derivative liability instruments - Non-current portion | — | — | ||||||||
Deferred taxes - Liabilities | Note 3.6.3 | 127 508 | 128 658 | |||||||
|
|
|
| |||||||
Non-current liabilities | 980 667 | 955 724 | ||||||||
|
|
|
| |||||||
Provisions - Current portion | Note 2.12 | 822 | 335 | |||||||
Borrowings and financial debts - Current portion | Note 2.13 | — | -1 | |||||||
Leasing debts - Current portion | Note 2.14 | 2 341 | 2 296 | |||||||
Trade and other payables | 33 243 | 43 931 | ||||||||
Current tax liabilities | Note 2.15 | 610 | 1 271 | |||||||
Other debts - Current portion | Note 2.15 | 28 405 | 18 163 | |||||||
Deferred income - Current portion | Note 2.16 | 137 | 191 | |||||||
Derivative liability instruments - Current portion | 952 | — | ||||||||
|
|
|
| |||||||
Current liabilities | 66 509 | 66 187 | ||||||||
|
|
|
| |||||||
LIABILITIES | 1 047 176 | 1 021 911 | ||||||||
|
|
|
| |||||||
TOTAL LIABILITIES AND EQUITY | 1 228 288 | 1 204 827 | ||||||||
|
|
|
|
4
STATEMENT OF PROFIT AND LOSS AND COMPREHENSIVE INCOME
Profit and Loss account
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||||||
Turnover | 255 923 | 201 543 | ||||||||||
Other income from operations | 605 | 1 384 | ||||||||||
Revenue from ordinary activities | Note 3.1 | 256 529 | 202 926 | |||||||||
Costs of sales | -73 681 | -56 635 | ||||||||||
Marketing and sales costs | Note 3.2 | -77 834 | -63 212 | |||||||||
General and administrative costs | Note 3.2 | -33 926 | -27 449 | |||||||||
Research and development costs | Note 3.2 | -9 062 | -9 418 | |||||||||
Other operating revenues | Note 3.3 | 1 874 | 1 561 | |||||||||
Other operating expenses | Note 3.3 | -2 204 | -11 178 | |||||||||
Other income | Note 3.4 | 111 | 8 031 | |||||||||
Other expenses | Note 3.4 | -4 675 | -24 338 | |||||||||
|
|
|
| |||||||||
Operating Result | 57 133 | 20 290 | ||||||||||
|
|
|
| |||||||||
Financial revenues | 2 205 | 1 251 | ||||||||||
Financial expenses | -59 559 | -55 188 | ||||||||||
|
|
|
| |||||||||
Financial Result | Note 3.5 | -57 354 | -53 937 | |||||||||
|
|
|
| |||||||||
Pre-tax Result | -221 | -33 648 | ||||||||||
Income/(expenses) from taxation | Note 3.6 | -2 872 | 6 439 | |||||||||
|
|
|
| |||||||||
Net Result | -3 093 | -27 209 | ||||||||||
|
|
|
| |||||||||
Of which: | ||||||||||||
Group share | -3 166 | -27 241 | ||||||||||
Non-controlling interest | 72 | 32 |
Basic and diluted earnings per share
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Basic and diluted earnings per share | -0,09 | -0,76 | ||||||
Other comprehensive income | ||||||||
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Net Result | -3 093 | -27 209 | ||||||
Revaluation of net defined benefit liability (asset) | -154 | 191 | ||||||
Related taxes | 42 | -55 | ||||||
|
|
|
| |||||
Total items that will not be reclassified to income in the future | -112 | 135 | ||||||
|
|
|
| |||||
Exchange differences | 1 045 | -282 | ||||||
Gains / losses at fair value | 193 | 255 | ||||||
|
|
|
| |||||
Total items likely to be reclassified to profit or loss in the future | 1 238 | -28 | ||||||
|
|
|
| |||||
Other components of comprehensive income | 1 126 | 108 | ||||||
|
|
|
| |||||
Total Global Result | -1 967 | -27 101 | ||||||
|
|
|
| |||||
Of which: | ||||||||
Group share | -2 042 | -27 132 | ||||||
Non-controlling interests | 75 | 32 |
5
CONSOLIDATED STATEMENT OF CASH FLOWS
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||||
Loss of fully consolidated companies before tax | -221 | -33 648 | ||||||||
Interest charges | 57 085 | 52 739 | ||||||||
Net provision for amortization | 2 795 | 4 244 | ||||||||
Net allocation for amortization of usage right - IFRS 16 | 2 379 | 2 419 | ||||||||
Net provision for amortization (revaluation of assets - PPA Astorg) | 1 237 | 3 806 | ||||||||
Net allocation to provisions | 904 | -530 | ||||||||
Capital gains and losses on the disposal of tangible and intangible assets and cost of disposa | 193 | 8 907 | ||||||||
Operating working capital | 541 | 13 478 | ||||||||
Stocks | 9 238 | -7 634 | ||||||||
Trade and other receivables | -4 001 | 19 637 | ||||||||
Trade and other payables | -4 696 | 1 475 | ||||||||
|
|
|
| |||||||
Cash flows generated by operating activities | 64 913 | 51 415 | ||||||||
|
|
|
| |||||||
Tax income / (expenses) paid | -1 355 | -71 | ||||||||
Other components of operational activities | 339 | -619 | ||||||||
|
|
|
| |||||||
Net cash flow from operational activities | 63 897 | 50 725 | ||||||||
|
|
|
| |||||||
Acquisition of tangible assets | Note 2.3 | -427 | -196 | |||||||
Acquisition of intangible assets | Note 2.2 | -12 217 | -11 031 | |||||||
Changes in payables to suppliers of fixed assets | 3 298 | -7 022 | ||||||||
Change in financial assets | -1 026 | -43 | ||||||||
Change in the scope | -174 | |||||||||
Other components of investment activities | -2 | — | ||||||||
|
|
|
| |||||||
Net cash flow used in investment activities | -10 546 | -18 292 | ||||||||
|
|
|
| |||||||
Loan repayments | Note 2.13.1 | -18 000 | -35 030 | |||||||
New borrowings | Note 2.13.1 | 10 000 | 28 000 | |||||||
Repayment of leasing debts | -2 521 | -2 355 | ||||||||
Interest paid | -20 650 | -21 264 | ||||||||
Other components of financing activities | 67 | 204 | ||||||||
|
|
|
| |||||||
Net cash flow used in financial activities | -31 103 | -30 446 | ||||||||
|
|
|
| |||||||
Net cash flow | 22 249 | 1 988 | ||||||||
|
|
|
| |||||||
Opening cash | 18 163 | 16 259 | ||||||||
Effects of exchange rate fluctuations on hedging cash flow | 163 | -84 | ||||||||
Closing cash | 40 575 | 18 163 | ||||||||
|
|
|
| |||||||
Net cash increase / (decrease) | 22 249 | 1 988 | ||||||||
|
|
|
|
6
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
In thousands of euros | Share capital | Share premium | Translation reserves | Fair value reserves | Consolidation reserves | Reserves - Actuarial gains and losses | Equity component of convertible bonds | Profit or loss | Total transactions with owners of the Company | Non- controlling interests | Total shareholders’ equity | |||||||||||||||||||||||||||||||||
Equity as of January 1, 2020 | 35 862 | 319 897 | 72 | 6 564 | - 96 975 | - 243 | 9 636 | - 65 014 | 209 799 | — | 209 799 | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Total income for the period | ||||||||||||||||||||||||||||||||||||||||||||
Net income | - 27 241 | - 27 241 | 32 | - 27 209 | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive income | - 236 | 255 | - 62 | 153 | 109 | -2 | 107 | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Total income for the period | — | — | - 236 | 255 | - 62 | 153 | — | - 27 241 | - 27 131 | 29 | - 27 102 | |||||||||||||||||||||||||||||||||
Transactions with the Company’s owners | — | — | ||||||||||||||||||||||||||||||||||||||||||
Contributions and distributions | — | — | ||||||||||||||||||||||||||||||||||||||||||
Other variances | 220 | 220 | 220 | |||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Total contributions and distributions | — | — | - 236 | 255 | 158 | 153 | — | - 27 241 | - 26 911 | 29 | - 26 881 | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Equity as of December 31, 2020 | 35 862 | 319 897 | - 165 | 6 818 | - 96 816 | -90 | 9 636 | - 92 254 | 182 888 | 29 | 182 917 | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Equity as of January 1, 2021 | 35 862 | 319 897 | - 165 | 6 818 | - 96 816 | -90 | 9 636 | - 92 254 | 182 888 | 29 | 182 917 | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Total income for the period | ||||||||||||||||||||||||||||||||||||||||||||
Net income | - 3 166 | - 3 166 | 72 | - 3 094 | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive income | 1 039 | 193 | - 112 | 1 120 | 6 | 1 126 | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Total income for the period | — | — | 1 039 | 193 | — | - 112 | — | - 3 166 | - 2 046 | 78 | - 1 968 | |||||||||||||||||||||||||||||||||
Transactions with the Company’s owners | — | — | ||||||||||||||||||||||||||||||||||||||||||
Contributions and distributions | — | — | ||||||||||||||||||||||||||||||||||||||||||
Other variances | 59 | 104 | 163 | 163 | ||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Total contributions and distributions | — | — | 1 098 | 193 | 104 | - 112 | — | - 3 166 | - 1 883 | 78 | - 1 805 | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Equity as of December 31, 2021 | 35 862 | 319 897 | 934 | 7 011 | - 96 713 | - 201 | 9 636 | - 95 420 | 181 006 | 107 | 181 112 | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
1 ACCOUNTING PRINCIPLES AND METHODS
1.1 Reporting Entity
The parent company, Héra S.A.S. (hereinafter “the Company”) is a company domiciled in France with its registered office in Chatillon 92320, 200 avenue de Paris; it was established on November 16, 2015.
The financial statements of the Company and its subsidiaries controlled, directly or indirectly, by the Company are included in the consolidated financial statements.
The Héra Group (hereafter “the Group”) aspires to be a global leader in the development and commercialization of pharmaceuticals, medical devices, and cosmetics.
The Group is comprised of the following companies:
Entities | Country | % holding | ||||
Héra Sas | France | Mother | ||||
Laboratoire HRA Pharma Sas | France | 100,00 | % | |||
HRA Pharma France Sas | France | 100,00 | % | |||
HRA Pharma Development Sarl | France | 100,00 | % | |||
HRA Pharma Deutschland GmbH | Germany | 100,00 | % | |||
HRA Pharma UK & Ireland Limited | UK | 100,00 | % | |||
HRA Pharma Italia Srl | Italy | 100,00 | % | |||
HRA Pharma Iberia SL | Spain | 100,00 | % | |||
HRA Pharma LLC | USA | 100,00 | % | |||
HRA Pharma Switzerland Sarl | Switzerland | 100,00 | % | |||
HRA Pharma Rare Diseases Sas | France | 100,00 | % | |||
HRA Pharma Benelux | Belgium | 100,00 | % | |||
HRA Pharma America Inc | USA | 100,00 | % | |||
HRA Pharma APAC | Hong Kong | 100,00 | % | |||
HRA Pharma Hong Kong Limited | Hong Kong | 67,00 | % | |||
HRA Pharma China | China | 100,00 | % |
1.2 Accounting principles
The consolidated financial statements were approved by the Chairman on March 23, 2022.
1.2.1 Statement of compliance and accounting principles
The consolidated financial statements have been prepared on the basis of IFRS (International Financial Reporting Standards) as adopted by the European Union, IFRS as issued by the IASB (International Accounting Standard Board) and interpretations of international standards (SIC and IFRIC) as of December 31, 2020 and 2021.
All of the European Union’s adopted texts can be found on the European Commission’s website at the following location:
http://ec.europa.eu/commission/index_fr
8
Effective January 1, 2021, the following standards and interpretations will apply:
The IASB’s published standards, revisions to standards, and interpretations that are mandatory as of the fiscal year 2021 are given below:
• | Amendments to IFRS 4 “Extension of the temporary exemption from IFRS 9” |
• | Amendments to IFRS 9, IAS 39 and IFRS 7 “Reform of reference interest rates - Phase 2” |
• | Amendments to IFRS 16 “Covid-19 rent concessions beyond June 30, 2021” |
• | Agenda decision of the IFRS Interpretations Committee (IFRS IC): Attributing Benefit to Periods of Service (IAS 19) |
The impact of these standards is not significant in the financial statements as of December 31, 2021.
Standards, amendments and interpretations published but not yet endorsed by the European Union and Standards, amendments and interpretations endorsed by the European Union and not early adopted by the Group:
The estimated impact of applying the IASB’s (International Accounting Rules Board) and IFRS IC’s (International Financial Reporting Standards Interpretations Committee) standards and interpretations, is not significant.
1.2.2 Basis of measurement and presentation
With the exception of specific asset and liability classes, the consolidated financial statements are prepared on a historical cost basis in accordance with IFRS. The relevant classes are listed in the notes below, as applicable.
Assets and liabilities of different types, functions, and sizes are shown individually.
Current assets and liabilities are those included in the working capital used throughout a normal business cycle. Current and non-current assets and liabilities are categorized according to whether they are due within one year as of the balance sheet date.
1.2.3 Functional and reporting currency
An entity’s functional currency is the currency of the economic environment in which it is principally active. The functional currency for subsidiaries is the local currency.
The Company’s functional currency is the euro, hence the consolidated financial statements are presented in euros. Unless otherwise stated, all financial data is expressed in thousands of euros.
1.2.4 Conversion of foreign currency transactions
Foreign currency transactions are translated into the relevant functional currencies of Group entities using the exchange rate in effect at the time of the transactions, in accordance with IAS 21.
Monetary assets and liabilities denominated in foreign currencies are converted into the functional currency at the balance sheet date using the closing rate. Exchange gains and losses are recorded in the income statement as a result of the relevant exchange variations.
1.2.5 Translation of financial statements of foreign subsidiaries whose functional currency is not the euro
Foreign subsidiaries whose functional currency is not the euro have their financial statements translated into euros as follows:
• | the balance sheets of foreign subsidiaries are translated into euros using the exchange rate prevailing at the balance sheet date; |
9
• | the income statements and cash flows of these companies are translated using the average exchange rate for the period; |
• | differences arising from the translation of the financial statements of foreign companies are recorded in other comprehensive income under the heading “Exchange differences”. |
1.2.6 Use of Judgments and Estimates
Management must use judgment and make estimates and assumptions while preparing financial statements, which affect the application of accounting policies and the reported values of assets and liabilities, income and expenses. Actual values may differ from those estimated due to changes in assumptions or economic conditions that differ from those in effect at the time the balance sheet was prepared.
The estimates and underlying assumptions are reviewed on an ongoing basis. The impact of changes in accounting estimates is recognized in the period of the change and any subsequent periods affected.
The following are some examples of key estimates and judgments used in adopting accounting policies:
• | the valuation of goodwill and intangible assets; |
• | the valuation of employee benefits; |
• | the valuation of provisions for risks, particularly in the event of litigation; |
• | deferred tax assets on losses carried forward. |
1.3 Main accounting principles
1.3.1 Consolidation method
The Group controls a subsidiary when it has power over the subsidiary, is exposed or has rights to variable returns from its involvement with the subsidiary and has the ability to use its power to affect the amount of its returns.
1.3.2 Business combinations
The acquisition method is used to account for business combinations. At the time of exchange, the consideration transferred is the fair value of the assets given, equity instruments issued, and liabilities incurred. Direct costs incurred as a result of the combination are recorded in “Other operating expenses” in the period in which they occur.
Except for particular exceptions provided for in the revised IFRS 3, the assets, liabilities, and contingent liabilities of the acquired firm are measured at fair value on initial consolidation of a controlled company.
Goodwill recorded in the consolidated balance sheet represents the difference between:
• | the aggregate of the following components: |
• | the consideration transferred for the acquisition of control; |
• | the amount of non-controlling interests in the acquired company, determined either at fair value at the acquisition date (full goodwill method) or on the basis of their proportionate share of the fair value of the net identifiable assets and liabilities acquired (partial goodwill method). This option is available on a transaction-by-transaction basis; |
• | for step acquisitions, the fair value at the acquisition date of the Group’s share of the net assets acquired prior to the acquisition of control; |
• | and the net amount of identified assets acquired and identified liabilities incurred, measured at their fair value at the acquisition date. |
10
After initial recognition, goodwill are tested for impairment in accordance with IAS 36 – Impairment of Assets, at least once a year and whenever there is an indication that the asset may be impaired.
The difference is recognized directly in the income statement when the consideration transferred is less than the fair value of the Group’s share of the identifiable assets acquired and liabilities assumed of the subsidiary acquired.
When the accounting for a business combination may only be determined provisionally, IFRS 3 requires that the asset and liability values be adjusted within twelve months of the acquisition date.
Adjustments to the values recognized after the measurement period expires in relation to the values assigned to the assets acquired and liabilities assumed on initial consolidation are recognized prospectively in profit or loss for the year of the change and subsequent years, if any, without adjustment to goodwill.
If the changes in the initial accounting for the combination are due to an error, the values assigned to the acquired assets and liabilities, non-controlling interests, or purchase price elements are changed retrospectively, as if their corrected fair values had been recognized as of the acquisition date. Goodwill must also be adjusted accordingly, and the impact of the error correction is recognized in opening equity in the year of the error correction, in accordance with IAS 8 - Accounting policies, changes in accounting estimates and errors.
1.3.3 Development costs
Research costs for the purpose of acquiring new scientific or technical knowledge and understanding are expensed as incurred.
Development activities involve the existence of a plan or design for producing new or substantially improved products and processes. Development expenditure is recognized as an asset if and only if the costs can be reliably measured and the Group can demonstrate:
• | the technical and commercial feasibility of the product or process in the short term; |
• | the recognition of probable future economic benefits; |
• | and its intention and the availability of sufficient resources to complete the development and use or sell the asset. |
The cost of materials and directly relevant subcontracting costs required to bring the asset to its intended use are included in the expense so capitalized.
Other development costs are expensed as incurred.
With the exception of products that have an active or exploitable marketing authorization and are capable of generating future economic benefits, or that are related to the safety of the environment or people, or that are indispensable for the continuation of the business, Héra believes that the criteria laid out in IAS 38 “Intangible Assets” have not yet been met, given the risks inherent in development programs and the progress of the Group’s projects.
1.3.4 Other intangible assets
Other intangible assets include intangible assets with an indefinite useful life (trademarks and property rights acquired from a third party for drugs) as well as patents, software, licenses, and marketing authorizations acquired or developed internally by the Group with a finite useful life. They are valued at the cost of acquisition (purchase price and related expenses).
Subsequent spending on intangible assets is recognized only if it boosts the asset’s future economic benefits. Other expenses are deducted as they are incurred.
Amortization is recognized over the expected useful life of intangible assets on a straight-line basis:
• Patents: | 20 years | |
• Development costs: | between 3 and 15 years | |
• Other intellectual property rights and licenses: | between 3 and 19 years |
11
• Software: | 1 to 3 years | |
• Licenses: | between 3 and 10 years | |
• Domain names: | between 1 and 5 years |
1.3.5 Property, plant and equipment
Property, plant and equipment are initially recognized at acquisition cost.
If it is expected that future economic advantages connected with the asset will flow to the Group and the cost of the asset can be determined accurately, subsequent costs are included in the carrying amount of the asset or, where appropriate, recognized as a distinct asset.
Fixed assets are depreciated on a straight-line basis over the estimated useful life of the assets. Depreciation is recognized as an expense for the year.
The estimated useful lives are as follows:
• Fixtures and fittings | 8 years | |||
• Industrial equipment | 10 years | |||
• Office and computer equipment | 3 years | |||
• Furniture | 10 years |
Depreciation methods, useful lives and residual values are reviewed and, if necessary, adjusted at each balance sheet date.
1.3.6 Financial assets and liabilities
Financial assets and liabilities mainly include:
• | Group investments (non-consolidated investments, debt securities, etc.) |
• | Loans and financial receivables |
• | Cash and cash equivalents |
• | Borrowings and other financial liabilities |
• | Derivative instruments |
Financial assets
Contractual characteristics and management models are used to classify financial assets.
Non-recyclable financial assets at fair value through other comprehensive income
The Group has made the irreversible decision to record investments in equity instruments at fair value through non-recyclable “other comprehensive income,” i.e., without the ability to transfer them to the income statement in the case of a sale. Only dividends received are recorded in the income statement.
Recyclable financial assets at fair value through other comprehensive income
Investments in debt instruments with a cash flow collection and resale mechanism and contractual flows consisting entirely of principal repayments and interest payments are reported at fair value with an offsetting entry in recyclable “other comprehensive income” (recyclable OCI).
Financial assets at fair value through profit or loss
Financial assets classified as fair value through profit or loss are financial assets purchased with the goal of resale in the near future or equity instruments for which the Group has not opted to define them as fair value through other comprehensive income.
12
Loans
Loans are measured at amortized cost if the business model is to collect contractual cash flows consisting solely of principal and interest payments.
The effective interest rate technique is used to account for interest in the income statement’s “Other financial income and costs.”
The Group has taken an approach to loan impairment that is based on the counterparty’s likelihood of default and its assessment of the credit risk’s progression. The difference between the carrying amount and the value of the expected future cash flows, discounted at the financial assets’ original effective interest rate, is the impairment loss.
Trade and other receivables
Trade receivables are recognized and recorded at their transaction price.
A depreciation is recognized based on the expected losses since the origin of the receivable. Bad debts are recognized as losses when they are identified as such.
Cash and cash equivalents
Cash equivalents are short-term, liquid investments that are readily convertible into a known amount of cash and which are subject to an insignificant risk of change in value. Cash and cash equivalents therefore includes cash at bank and in hand, as well as cash investments in marketable securities with a maturity of three months or less and with very low sensitivity to interest rate risk.
In the cash flow statement, cash and cash equivalents comprise cash in hand, demand deposits in banks, and short-term liquid investments, net of bank overdrafts. It should be noted that bank overdrafts are included in the balance sheet under “Borrowings - current portion”.
Financial liabilities
Borrowings and financial debts
Bank loans are initially valued at fair value of the consideration received, minus transaction costs that are directly traceable.
They are then measured using the effective interest rate approach at amortized cost. Specifically, using the effective interest rate method, all costs associated with the issuance of loans or bonds, as well as any difference between the issuance proceeds net of transaction costs and the redemption value, are recognized in the income statement as financial expenses over the life of the loans.
Compound instruments
Compound financial instruments issued by the Group in euros include convertible bonds which give the holder the option to convert them into a specified number of shares.
The liability component of the compound financial instrument is initially valued at the fair value that a similar liability would have if it did not have a conversion option. The equity component is the difference between the fair value of the entire compound financial instrument and the fair value of the liability component when it is first recognized.
The liability component of a compound financial instrument is measured at amortized cost using the effective interest method after initial recognition. After initial recognition, the equity component of the compound financial instrument is not remeasured.
The income statement accounts for interest on financial liabilities.
13
Derivative instruments
Hedging transactions in the form of derivative instruments, such as forward contracts, currency options, and interest rate options, are used by the Group to manage market risks (interest and exchange rates).
According to the standards of IFRS 9, these financial products are designated as hedging instruments and are primarily accounted for as cash flow hedges.
Hedge accounting
A cash flow hedge protects against the risk of profit or loss from variations in cash flows of an asset, obligation, or highly probable projected transaction that are linked to one or more risk components.
For the effective portion of the hedging relationship, changes in the fair value of the hedging instrument are recognized directly in the consolidated statement of comprehensive income, and for the ineffective portion, they are recorded in the income statement.
When the hedged transaction affects the income statement, cumulative changes in the fair value of the hedging instrument previously recognized in the consolidated statement of comprehensive income are recycled to the income statement.
Gains and losses are recorded in “Other operating income” for hedging operational activities and “Financial income” or “Financial expense” for hedging investment and financing activities.
The cumulative changes in the fair value of the hedging instrument previously recorded in the consolidated statement of comprehensive income are included in the initial measurement of the asset or liability concerned when the forecasted transaction results in the recognition of a non-financial asset or liability.
Hedging cost
The Group may document currency or interest rate options as hedging instruments as part of its market risk management policy, and the effectiveness of these products is assessed based on changes in intrinsic value. Depending on the nature of the risk hedged, the time value of these options is handled as a hedging cost and recognized in the consolidated statement of comprehensive income and recycled to the income statement.
Discontinuation of hedge accounting
When the criteria for hedge accounting’s application are no longer met, such as when the hedging instrument expires, is sold, terminated, or exercised, or when the hedging relationship’s market risk management purpose changes, hedge accounting is discontinued.
IBOR reform
A reform of the main reference rates is underway with the replacement of Interbank Offered Rates (IBOR) by alternative risk-free reference rates.
The Group is closely monitoring market activity as well as the publications of various bodies, particularly the IFRIC and the IASB, and has prepared itself for a gradual transition to risk-free rates.
Financial instruments (finance and derivatives) and, to a lesser extent, certain commercial contracts are likely to be affected by this reform (late payment interest, etc.).
In this context, the IASB has published several amendments to IFRS 9 and IFRS 7, including phase 2, which was adopted on January 13, 2021 and went into effect on January 1, 2021, to reflect the impact of replacing benchmark interest rates with new benchmark interest rates without any accounting impact that would not provide useful information to financial statement users.
14
The Group’s financial statements for 2021 are unaffected by this rate change.
1.3.7 Inventories and work in progress
The cost of inventory is determined using the F.I.F.O. (First In, First Out) method. The cost of inventories includes all direct material costs, labor costs and the allocation of indirect production costs and/or subcontracting costs.
Inventories are measured at cost or net realizable value if lower than the net book value.
An impairment loss is recognized when:
• | products are damaged and therefore, not saleable; |
• | products that have expired or are nearing obsolescence between 0 and 12 months before the expiration date. |
1.3.8 Employee benefits
In accordance with the specific laws and provisions of each country in which it operates, the Group provides its employees with post-employment benefits (pension plans, termination benefits, etc.).
Defined contribution plans
A defined contribution plan is a post-employment benefit plan in which a company makes pre-determined contributions to a separate company and is under no legal or constructive duty to pay additional contributions. When contributions to defined contribution plans are due, they are recorded as an expense. Prepaid contributions are classified as assets if they may result in a cash refund or a reduction in future payments.
Defined benefit plans
A defined benefit plan is a post-employment plan other than a defined contribution plan.
Employees’ future benefits are estimated in exchange for services given in the current and preceding periods, and liabilities under defined benefit plans are measured separately for each plan. A certified actuary performs annual actuarial valuations using the predicted unit credit approach. This technique involves calculating the rights that employees have earned at the end of the year for all plans, taking into consideration the outlook for wage increases and the economic conditions in each country.
For post-employment benefits, the valuation is based in particular on the following methods and assumptions:
• | the retirement age, determined on the basis of the provisions applicable to each of the schemes and the conditions required to qualify for a full pension; |
• | the projected salary level at retirement, taking into account the expected career progression and the estimated change in the retirement age; |
• | the projected number of retirees determined on the basis of staff turnover rates and mortality tables available in each country; |
• | the discount rate determined at the balance sheet date by reference to the rate on high quality corporate bonds with a duration close to that of the Group’s obligations. |
The net expense recognized during the year for employee benefits includes:
- | in the Profit & Loss account: |
• | the service cost corresponding to the acquisition of additional rights; |
15
• | the net interest cost, corresponding to the interest cost on obligations net of income from hedging assets, now measured using the discount rate for obligations; |
• | past service cost, including the expense or income arising from plan amendments/liquidation or the introduction of new plans; |
• | actuarial gains and losses relating to other long-term benefits. |
- | in the statement of net income and gains and losses recognized directly in other comprehensive income: |
• | actuarial differences relating to post-employment benefits. |
Termination benefits
When the Group is manifestly committed to a specific formal strategy for either termination of employment before the typical retirement date or an offer to induce voluntary redundancy with the goal of decreasing the workforce, termination benefits are recognized as an expense. If the Group has made an offer to encourage voluntary redundancies, it is likely that the offer will be accepted, and the number of employees who will accept the offer can be reasonably anticipated, voluntary redundancy payments are recorded as an expense.
Short-term benefits
If the Group has a present legal or constructive obligation to make such payments in return for past service rendered by the employee and the obligation can be reliably estimated, a provision is recognized for the amount that the Group expects to pay in respect of short-term cash-settled incentive and profit-sharing plans and bonuses.
1.3.9 Share-based payments
Over the time during which the staff members definitively acquire the rights, the fair value established at the date of grant of the options issued to employees is recognized as an employee benefit expense, with a corresponding rise in equity. The expense amount is adjusted to reflect the actual number of vested options for which the service and performance standards are met.
The fair value of the amount to be settled to an employee for cash-settled share appreciation rights is recognized as an expenditure, with a corresponding rise in the liability, over the period in which the employees become entitled to the final payment. At each balance sheet date and at the settlement date, the liability is remeasured. Personnel expenses account for any changes in the liability’s fair value.
Regardless of how the Group obtains the equity instruments, share-based payment transactions in which the Group receives goods or services in exchange for its own equity instruments are accounted for as equity-settled transactions.
The standards of IFRS 2 are used to measure and recognize plans that have been authorized but have not yet vested as of December 31, 2021.
1.3.10 Provisions
Provisions are accounted for when the Group has a present legal or constructive obligation as a result of a past event, the obligation can be reliably estimated and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation.
These provisions are calculated based on the most likely assumptions at the time of the balance sheet.
16
1.3.11 Revenue from ordinary activities
1.3.11.1 Turnover
The Group’s revenue consists primarily of revenue from the sale of pharmaceutical products and medical devices. It is recognized when control of the goods or services is transferred to the client generally upon delivery, in accordance with the delivery and acceptance terms of the contract with the customer. Revenue is accounted for at the amount that reflects the sums that the Group expects to receive.
Revenue from product sales consists of the sale of products net of returns, rebates, discounts and allowances granted to customers. Rebates, discounts and rebates are recognized concurrently with the sales to which they relate and are identified as a variable component of the price in accordance with the provisions of IFRS 15.
1.3.11.2 Other income from operations
Other revenue includes royalties, income from licensing agreements with partners and other services.
Royalties received are recorded under “Royalties and Downpayments” on the basis of revenues generated by partners during the fiscal year and the contractual royalty rates.
1.3.12 Research Tax Credit
The French government provides tax incentives to businesses to encourage them to conduct technological and scientific research. Companies that can show that they have incurred expenses that meet the criteria (research expenses incurred in France, the European Union, or another country that has signed a tax treaty with France containing an administrative assistance clause since January 1, 2005) are eligible for a tax credit that can be used to pay corporate income tax. Except for the research tax credit arising from capitalized expenses, which is accounted for first as deferred income and then as a deduction from development costs as the expenses are amortized, this research tax credit is accounted for as a grant, as a deduction from recognized research and development costs.
1.3.13 Cost of sales and other operating expenses
The costs of manufacturing the marketed products are included in the sales costs.
The costs of distribution, promotion, and sale of pharmaceuticals are all included in marketing expenditures.
General management and support tasks are included in general and administrative costs (finance, IT, HR, etc.).
Internal and external costs of research and development studies that do not meet the criteria for the activation of new products, as well as regulatory affairs expenses, are included in research and development expenses.
1.3.14 Other income and expenses
Other income and expenses include a limited number of income and expenses, such as:
• | gains and losses on disposals of non-current tangible or intangible assets; |
• | impairment of non-current tangible or intangible assets; |
• | amortization of intangible assets acquired in business combinations; |
• | restructuring costs; |
• | provisions relating to major litigation for the company. |
17
1.3.15 Lease agreements
For all leases, regardless of their nature, the Group recognizes leases as assets in the form of a right of use against a rental liability on the balance sheet. The Group recognizes a depreciation charge and an interest charge in the profit and loss account, and lease payments are included in cash flows from financing activities in the cash flow statement.
Property leases and vehicle leases are the two principal contracts affected by the standard.
1.3.16 Financial income and expenses
Net financial income / (loss) includes interest on investments, interest payable on borrowings calculated using the effective interest method, changes in the fair value of financial assets at fair value through profit or loss, impairment losses recognized in respect of financial assets, foreign exchange gains and losses on financial transactions, foreign exchange differences and discounting and undiscounting effects.
When interest income is earned using the effective interest technique, it is recorded in the income statement.
1.3.17 Income tax
Current tax expense/income and deferred tax expense/income are both included in income tax (expense or income).
Tax is included in profit or loss unless it is related to items that are directly recorded in other comprehensive income or equity, in which case it is recorded in the same manner.
Current tax is defined as (i) the estimated amount of tax payable in respect of taxable profit for a period, calculated using tax rates enacted or substantively enacted at the balance sheet date, and (ii) any adjustment to the amount of tax payable in prior periods.
Unless otherwise specified, all transitory differences between the carrying amount of assets and liabilities and their tax bases are determined and recorded using the balance sheet liability technique. Based on tax regulations that have been passed or substantively enacted by the balance sheet date, deferred tax assets and liabilities are measured at the tax rates that are projected to apply to the period when the asset is realized and the liability is settled.
Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax assets and liabilities and they relate to income taxes levied by the same taxation authority, either on the same taxable entity or on different taxable entities, but which intend to settle the current tax assets and liabilities on a net basis or to realize the assets and settle the liabilities at the same time.
A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each balance sheet date and are recognized to the extent that it is probable that sufficient taxable profit will be available.
Deferred taxes are calculated using domestic tax rates that are projected to apply when the asset is realized and the liability is resolved, based on tax rates that have been enacted or substantially enacted by the balance sheet date, depending on the jurisdiction.
As a result, as of December 31, 2021, deferred taxes for French corporations have been recognized at the rates approved by the French National Assembly (including the 3.3% social contribution) based on the reversal schedules below:
• | 27.37% in 2021; |
• | 25.83% in 2022 and beyond. |
18
1.3.18 Earnings per share
Basic earnings per share are calculated by dividing the profit or loss attributable to ordinary and preference shareholders of the Company by the weighted average number of ordinary shares outstanding during the period.
Diluted earnings per share are determined by adjusting the profit or loss attributable to ordinary and preference shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares (bonus share grants, warrants and stock options granted to beneficiaries).
1.3.19 Impairment testing of non-financial assets
In accordance with IAS 36 - Impairment of Non-Financial Assets, goodwill, trademarks, and non-amortizable rights of use are tested for impairment at least once a year, or more frequently if there is an indication of impairment. If there is any sign of impairment, additional assets are also subjected to impairment assessments.
In addition, at each balance sheet date, the carrying amounts of other intangible assets are examined to see whether there is any indication that the asset may be impaired. If such an indicator exists, the asset’s recoverable value is estimated.
The success of subsequent rounds of clinical research, pharmacovigilance, patent protection, the arrival of competitor treatments, or changes in actual sales compared to expectations can all be indicators of impairment.
Goodwill and assets identified in a business combination are allocated to one of the Group’s two cash-generating units, CHC (i.e., the sale of products in pharmacies, supermarkets, or e-commerce outlets and, for the most part, without prescription) and RX (i.e. the sale of prescription products and mainly comprising the rare disease activities), for the purposes of impairment testing, from the date of acquisition. These assets include, in particular, emergency contraceptive products (Compeed and Mederma), as well as RX.
Impairment tests consist of comparing the net book value of the asset or cash-generating unit with its recoverable amount, which is the higher of its fair value less costs to sell and its value in use.
Value in use is calculated as the sum of the discounted cash flows expected from the use of the asset or cash-generating unit and its ultimate disposal.
The amount that may be collected through the sale of an asset or cash-generating unit in an arm’s length transaction, minus costs directly related with the disposal, is known as fair value less costs to sell.
The Group’s weighted average cost of capital is used to discount the expected cash flows.
If the carrying value of an asset or its cash-generating unit exceeds its recoverable value, an impairment loss is recognized. Losses due to impairment are recorded in the income statement. A cash-generating unit’s impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the cash-generating unit, and then to reduce the carrying amounts of the unit’s other assets pro rata to the carrying amount of each asset in the unit.
The methods and key assumptions specific to the asset impairment tests performed for the year ended December 31, 2021 are presented with respect to goodwill in note 2.1.
1.4 Determining fair value
The following are the valuation methodologies utilized at each level:
• | Level 1 (unadjusted quoted prices): prices available to the entity at the measurement date in active markets for identical assets or liabilities; |
• | Level 2 (observable inputs): data about the asset or liability other than quoted market prices included in Level 1 inputs that are observable either directly (such as a price) or indirectly (i.e. derived from observable prices); |
19
• | Level 3 (unobservable inputs): inputs that are not observable in a market, including observable inputs that are subject to significant adjustments. |
The following procedures were used to determine fair values for balance sheet measurement and disclosure.
(i) | Investment in equity and debt securities |
The fair value of listed financial instruments measured at fair value through profit or loss or through other comprehensive income is determined by comparing their last quoted bid price at the balance sheet date to their fair value or using recognized valuation techniques such as the discounted cash flow method if the instrument is not listed.
(ii) | Trade and other receivables |
The fair value of trade and other receivables is calculated using the present value of future cash flows, discounted at the current market interest rate.
(iii) | Non-derivative financial liabilities |
The present value of future cash flows generated by the debt (principal and interest) at the market interest rate adjusted for a credit spread at the reporting date is used to calculate fair value for disclosure purposes.
(iv) | Derivative instruments |
The fair value of derivatives is based on recognized valuation techniques such as the discounted cash flow method and includes credit risk (Credit Value Adjustment) and counterparty risk (Debit Value Adjustment).
1.5 Changes in accounting policies
The IFRIC’s agenda decision issued in May 2021 on attributing retirement benefits on length of services has no significant impact on the consolidated financial statements.
1.6 Significant events of the fiscal year period
1.6.1 Change of scope
• | As part of the Group’s development in Asia, particularly in China, HRA Pharma has established 3 entities in 2019: |
• | HRA Pharma APAC Limited, based in Hong Kong, was founded on December 10, 2019 with the goal of managing and supervising the company’s operations in Asia outside of China; |
• | HRA Pharma Hong Kong Limited, based in Hong Kong, was founded on December 10, 2019 and is responsible for managing and supervising the company’s operations in China; |
• | HRA Pharma China (WFOE), a Shanghai-based company founded on August 6, 2019. |
As of December 31, 2020:
• | HRA Pharma APAC and HRA Pharma China are wholly owned by HRA Pharma; |
• | HRA Pharma Hong Kong is 67% owned by HRA Pharma and 33% owned by the partner Profex; |
20
• | A capital of 700 thousand CNY was paid from HRA Pharma Laboratory to HRA Pharma China in June 2020; |
• | Activity in China began in April 2020. |
1.6.2 COVID-19
Financial year 2020:
The company has taken a targeted approach to conveying the most important impacts on the year’s performance and financial position.
The information presented pertains to the main impacts of the event that are recorded in the accounts, as judged appropriate. By measuring the gross and net impacts, these effects are described, taking into account the interactions and repercussions of the event on the normal aggregates. It is also evaluated in terms of the support measures from which it may have benefited.
The global epidemic known as “Covid-19” has had a detrimental influence on the Group’s operations, owing to containment and social distancing measures implemented in most nations throughout the world, particularly in Europe.
The impact on sales was felt most acutely in the “Consumer Healthcare” area, which had a 22% drop in sales, or - 44,564 thousand euros, compared to the previous year. The “Endocrinology” segment’s sales remained unaffected (+10% in comparison to 2019).
Despite the fact that practically all points of sale (pharmacies and supermarkets in particular) were open during these periods of confinement, there was a decline in sales.
The Group has attempted to mitigate the impact of Covid-19 on its profitability by cutting costs, particularly promotional expenses (-7%, or 2,462 thousand euros, compared to 2019) and development expenses (line item “Research and development expenses” in the income statement) (-16%, or -709 thousand euros compared with 2019).
It should be highlighted that the group’s manufacturing and transportation of products has not been disrupted.
With the prolongation of the €20 million senior loan took out in March 2020 and a new €8 million loan taken out with the BPI in September 2020, the company has strengthened its liquidity and has the required resources to ensure the company’s expansion.
Except for a suspension of payment of certain social security and tax expenses during the first confinement, the Group has not sought any remedy or aid from the government. At the end of the year, these deferrals were repaid up to 80%.
Financial year 2021:
The Group’s sales increased by more than 26% in 2021 compared to 2020, reflecting the strength of its brands as well as the recovery from the Covid-19 pandemic’s consequences.
After a negative impact from Covid-19 in 2020, Compeed branded revenues rebounded dramatically in 2021.
The Group concentrated on reducing and optimizing its material costs, notably in the area of “rare diseases” as well as its operating expenses, throughout this time. These efforts paid off with an operating profit of €57.1 million, up €36.8 million (+181.5%) over the previous year.
The Group’s inventory management has also been improved.
It should be emphasized that the Group’s manufacturing and supply of products has not been disrupted.
21
Except for the German subsidiary, which has received 594,000 euros since the initial restriction, the Group has not sought recourse or assistance from the government.
As of December 31, 2021, all deferred payments of certain social security and tax costs made at the time of the first containment have been repaid.
1.6.3 Buyback offer from PERRIGO
Perrigo made an offer to the shareholders Astorg and Goldman Sachs Asset Management on September 8, 2021, to buy 100% of the Group’s share capital.
This offer was accepted by the shareholders in early November 2021. The sale of the Group is still subject to antitrust approval in the United States, despite the fact that all other prerequisites have been completed.
The deal is expected to be completed in the first half of 2022.
1.6.4 Ongoing legal actions
Financial year 2020:
• | In May 2018, BILIM, a Turkish generics business, requested that the Turkish counterpart of the European patent EP 2,419,108, which covers the protection of ella, be declared illegal by the Ankara Court. |
Laboratoire HRA Pharma has filed its defense.
Laboratoire HRA Pharma withdrew the Turkish patent in January 2021, bringing the case to a close.
There were no financial or accounting implications.
• | In Europe, patent opposition procedures are pending before the European Patent Office, including the products ella and Esmya: |
• | Opposition to the patent on the formulation of ella and Esmya tablets: HRA has challenged the European Patent Office’s first instance ruling. We predict that the appeal hearing will take place in 2021, and that the appeal judgment will be announced in 2021, with no additional information. |
• | Opposition to the patent on the “Esmya” treatment: HRA filed an appeal; the hearing was place on November 23, 2020, and the European Patent Office revoked the patent. |
There were no financial or accounting consequences.
• | Opposition to the patent on the contraceptive method “ella”: HRA appealed the first instance judgement and filed an appeal brief; the hearing before the European Patent Office’s Board of Appeal was held on October 11, 2020, and the European Patent Office revoked the patent. |
There were no financial or accounting consequences.
• | Since early 2019, Laboratoire HRA Pharma and Vifor have engaged in a pre-litigation over the Esmya distribution contract in Australia and New Zealand. Laboratoire HRA Pharma sought 400 thousand euros under a condition that may be reduced if a disagreement arose. |
Vifor expressed dissatisfaction with HRA Pharma but did not make a quantifiable claim.
On April 8, 2020, a deal was reached; HRA acknowledged the idea of contract cancellation, and neither side is responsible for any payments.
There has been no provision made.
• | Esmya Canada is the subject of a lawsuit filed in August 2019 against Apotex (Fibristal). This is a patent infringement case involving the patent for tablet composition and the patent for indication. |
22
Two similar litigations were initiated involving AbbVie, the local distributor of Esmya, the US Government and HRA against Jamp Pharma in one case and Pharma Science in the other case.
AbbVie relinquished its marketing license for Fibristal, bringing the case to a close.
Financial year 2021:
• | In Europe, ella and Esmya products are the subject of a patent opposition proceeding before the European Patent Office: |
• | HRA filed an appeal against the European Patent Office’s first instance ruling on the patent for the formulation of ella and Esmya tablets. |
HRA has filed an appeal against the European Patent Office’s first instance revocation judgment. A summons to an oral hearing before the Board of Appeal in Harr (Germany) has been issued; the hearing is scheduled for November 24, 2022. By the end of 2022, a conclusive decision on the patent’s maintenance or revocation is expected.
• | HRA filed an infringement claim against four generic makers of ellaOne products with the District Court in Korea on December 23, 2021, based on the ellaOne “formulation” patent. |
• | A legal battle is underway with ella’s former Austrian distributor, who has sued HRA Pharma for non-delivery of supplies. |
SANOVA also blames HRA Pharma for terminating the contract with too little notice.
HRA Pharma intends to actively defend itself against this attack, it has recorded a provision of 150 thousand euros in its financial statements.
The court is now hearing the case.
1.6.5 Other Information
Financial year 2020:
• | European health authorities have conducted evaluations of the medication Esmya (containing the active ingredient ulipristal acetate for the treatment of uterine fibroids in 3-month cycles at 5mg per day). The most recent decision is that of the European Union, which agreed to keep the medicine on the market but with a drastically limited indication on January 11, 2021. |
The product’s marketing has been halted in practically every other country on the planet.
• | At the end of 2020, Laboratoire HRA Pharma’s management decided to put the “ELLIS” and “UPSI” projects on hold. As a result of this decision, items previously recognized as fixed assets have been removed for the following amounts: 8,666 thousand euros for ELLIS (net book value of 7,935 thousand euros) and 419 thousand euros for UPSI (net book value of 415 thousand euros). |
Financial year 2021:
• | HRA France’s “rare diseases” business was transferred to HRA Pharma Rare Diseases on April 1, 2021. |
• | HRA Pharma Development, which is wholly owned by Laboratoire HRA Pharma, was absorbed by the latter via a Universal Asset Transfer on December 31, 2021. |
23
• | On September 15, 2021, HRA Pharma LLC, which had no activity, was dissolved. |
• | From July 2021, the local subsidiary in the United Kingdom began marketing Hana, a regular contraceptive tablet. |
2 NOTES TO THE STATEMENT OF FINANCIAL POSITION
2.1 Goodwill
The goodwill shown in the December 31, 2021 balance sheet is the result of the acquisition of Laboratoire HRA Pharma in 2016 for an initial €303 million, the Compeed acquisition in 2017, the acquisition of the property rights of Lysodren in 2018, the acquisition of Mederma assets in June 2019 for €57 million.
At the end of the two fiscal years, goodwill had a balance of €530 million (gross €553 million minus a €23 million impairment).
Impairment testing
Impairment tests are conducted at the level of each of the two Cash Generating Units (CGUs): RX (the sale of prescription products, which primarily includes rare disease activities) and CHC (the sale of products in pharmacies, supermarkets, or e-commerce, which, for the most part, does not require a prescription). The CHC CGU includes, for example, emergency contraceptive medications such as Compeed and Mederma).
The recoverable amount of each cash-generating unit corresponds to its value in use, which is calculated using the discounted value of the expected future cash flows. The assumptions used for the impairment tests of each cash-generating unit are reviewed annually:
• | Business plan drawn up by management for the period 2022 to 2025 with structural costs allocated according to the weight of the activities of each CGU; |
• | Beyond this horizon, cash flows are extrapolated by applying the expected long-term market growth rate; |
• | An average tax rate has been used over the business plan horizon and corresponds to the weight of the activity in each area; |
• | A discount rate determined by geographical area, ranging from 8% to 9.2% depending on the cash generating units tested; |
• | Perpetual growth rate set at 2% for the calculation of terminal values of CGUs. |
24
The carrying amounts of the respective Cash Generating Units and the main assumptions are presented below:
in thousands of euros | RX | CHC | Total | |||||||||
Net book value as of December 31, 2020 | ||||||||||||
Goodwill | 63 879 | 465 707 | 529 585 | |||||||||
Net assets | 43 297 | 466 023 | 509 320 | |||||||||
Total | 107 176 | 931 730 | 1 038 905 | |||||||||
Perpetual growth rate | 2 | % | 2 | % | ||||||||
Discount rate | 8,2 | % | 8 | % | ||||||||
Net book value as of December 31, 2021 | ||||||||||||
Goodwill | 63 879 | 465 707 | 529 585 | |||||||||
Net assets | 41 934 | 475 816 | 517 750 | |||||||||
Total | 105 813 | 941 523 | 1 047 335 | |||||||||
Perpetual growth rate | 2 | % | 2 | % | ||||||||
Discount rate | 9,2 | % | 8,3 | % |
For the years 2020 and 2021, tests were conducted to determine the sensitivity of the recoverable amount to likely changes in various actuarial assumptions, primarily the discount rate (range +/- 1%), change in cash flows (range +/- 20%), and perpetual growth rate (range +/- 1%). The sensitivity analyses were calculated by changing a single parameter and did not result in the recognition of any risk of goodwill impairment.
For the years 2020 and 2021, no impairment of goodwill has been identified.
2.2 Intangible assets
The following are the changes in “intangible assets” over the last two years:
Gross value in thousands of euros | Development Costs | Concessions, patents, trademarks and licenses | Marketing authorizations and exploitation rights | Software | Other intangible assets | Total | ||||||||||||||||||
December 31, 2019 | 88 666 | 527 867 | 21 873 | 78 | 64 | 638 549 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Acquisitions | 10 420 | 350 | 39 | 222 | 11 031 | |||||||||||||||||||
Redeployment | 0 | |||||||||||||||||||||||
Sales / Scrapping | -9 064 | -730 | -6 | -23 | -9 823 | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
December 31, 2020 | 90 022 | 527 487 | 21 907 | 277 | 64 | 639 757 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Acquisitions | 11 349 | 128 | 726 | 15 | 12 217 | |||||||||||||||||||
Redeployment | 0 | |||||||||||||||||||||||
Sales / Scrapping | -195 | -10 | -205 | |||||||||||||||||||||
Exchange differences | 9 | 9 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
December 31, 2021 | 101 176 | 527 615 | 22 641 | 281 | 64 | 651 778 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Amortization in thousands of euros | Development Costs | Concessions, patents, trademarks and licenses | Marketing authorizations and exploitation rights | Software | Other intangible assets | Impairment losses | Total | |||||||||||||||||||||
December 31, 2019 | -41 138 | -20 253 | -13 806 | -59 | -2 | -52 139 | -127 397 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
Allowances | -4 512 | -166 | -1 470 | -54 | -1 210 | -7 412 | ||||||||||||||||||||||
Redeployment | 0 | |||||||||||||||||||||||||||
Sales / Scrapping | 788 | 129 | 5 | 24 | 946 | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
December 31, 2020 | -44 862 | -20 290 | -15 271 | -90 | -2 | -53 348 | -133 864 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
Allowances | -1 828 | -542 | -1 482 | -103 | 520 | -3 437 | ||||||||||||||||||||||
Redeployment | 186 | -186 | 0 | |||||||||||||||||||||||||
Sales / Scrapping | 2 | 10 | 11 | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
December 31, 2021 | -46 689 | -20 647 | -16 753 | -183 | -2 | -53 014 | -137 289 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25
Net value in thousands of euros | Development Costs | Concessions, patents, trademarks and licenses | Marketing authorizations and exploitation rights | Software | Other intangible assets | Impairment losses | Total | |||||||||||||||||||||
December 31, 2019 | 47 528 | 507 614 | 8 067 | 19 | 62 | -52 139 | 511 151 | |||||||||||||||||||||
December 31, 2020 | 45 160 | 507 197 | 6 636 | 187 | 62 | -53 348 | 505 893 | |||||||||||||||||||||
December 31, 2021 | 54 487 | 506 968 | 5 888 | 98 | 62 | -53 014 | 514 489 |
Intangible assets other than brands are amortized over a period of between 1 and 20 years.
Financial year 2020:
Over the fiscal year period, 78% of investments were made in the CGU “CHC”.
The drop in gross value is primarily due to the decision to freeze the “ELLIS” and “UPSI” projects in the “CHC” domain: 8,666 thousand euros for ELLIS (net book value of 7,935 thousand euros) and 419 thousand euros for UPSI (net book value of 415 thousand euros).
Financial year 2021:
Investments during the period mainly concern the CGU “CHC” for 89%.
2.3 Property, plant and equipment
The following is a breakdown of tangible assets:
Gross value in thousands of euros | Fixtures and fittings | Plant, machinery and equipment | Other tangible fixed assets | Total | ||||||||||||
December 31, 2019 | 1 375 | 2 356 | 1 386 | 5 117 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Acquisitions | 100 | 46 | 145 | |||||||||||||
Sales / Scrapping | -14 | -41 | -54 | |||||||||||||
Redeployment | 20 | 32 | 52 | |||||||||||||
Exchange differences | -6 | -5 | -12 | |||||||||||||
|
|
|
|
|
|
|
| |||||||||
December 31, 2020 | 1 375 | 2 456 | 1 418 | 5 249 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Acquisitions | 395 | 33 | 427 | |||||||||||||
Sales / Scrapping | -4 | -1 | -5 | |||||||||||||
Redeployment | 0 | |||||||||||||||
Exchange differences | 1 | 7 | 6 | 15 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
December 31, 2021 | 1 376 | 2 854 | 1 456 | 5 686 | ||||||||||||
|
|
|
|
|
|
|
|
26
Amortization in thousands of euros | Fixtures and fittings | Plant, machinery and equipment | Other tangible fixed assets | Total | ||||||||||||
December 31, 2019 | -181 | -702 | -341 | -1 224 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Allowances | -156 | -273 | -161 | -589 | ||||||||||||
Write-back on | 36 | 36 | ||||||||||||||
Redeployment | -20 | -32 | -52 | |||||||||||||
Exchange differences | 5 | 2 | 7 | |||||||||||||
|
|
|
|
|
|
|
| |||||||||
December 31, 2020 | -336 | -990 | -496 | -1 822 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Allowances | -155 | -280 | -163 | -598 | ||||||||||||
disposals/scrapping | 4 | 1 | 5 | |||||||||||||
Redeployment | 0 | |||||||||||||||
Exchange differences | -1 | -6 | -4 | -11 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
December 31, 2021 | -492 | -1 272 | -661 | -2 426 | ||||||||||||
|
|
|
|
|
|
|
|
Net value in thousands of euros | Fixtures and fittings | Plant, machinery and equipment | Other tangible fixed assets | Total | ||||||||||||
December 31, 2019 | 1 194 | 1 654 | 1 045 | 3 893 | ||||||||||||
December 31, 2020 | 1 039 | 1 466 | 922 | 3 427 | ||||||||||||
December 31, 2021 | 884 | 1 582 | 795 | 3 261 |
During the two years, no signs of deterioration were found.
2.4 Rights of Use associated with Leases
The following is a breakdown of the rights of use associated with leases:
Gross value in thousands of euros | Real estate property | Others | Total | |||||||||
December 31, 2019 | 12 222 | 1 549 | 13 771 | |||||||||
|
|
|
|
|
| |||||||
Initial application of IFRS 16 | 146 | 719 | 865 | |||||||||
Acquisitions | 20 | 20 | ||||||||||
Sales / Scrapping | -44 | -149 | -193 | |||||||||
Redeployment | 0 | |||||||||||
Exchange differences | -62 | -0 | -62 | |||||||||
|
|
|
|
|
| |||||||
December 31, 2020 | 12 282 | 2 119 | 14 401 | |||||||||
|
|
|
|
|
| |||||||
Acquisitions | 566 | 575 | 1 141 | |||||||||
Sales / Scrapping | -58 | -404 | -462 | |||||||||
Redeployment | 0 | |||||||||||
Exchange differences | 70 | 70 | ||||||||||
|
|
|
|
|
| |||||||
December 31, 2021 | 12 860 | 2 290 | 15 150 | |||||||||
|
|
|
|
|
|
27
Amortization in thousands of euros | Real estate property | Others | Total | |||||||||
December 31, 2019 | -1 675 | -622 | -2 297 | |||||||||
|
|
|
|
|
| |||||||
Allowances | -1 823 | -597 | -2 419 | |||||||||
Opening adjustment | -18 | 1 | -17 | |||||||||
Write-back on disposals/scrapping | 44 | 137 | 181 | |||||||||
Redeployment | 0 | |||||||||||
Exchange differences | 24 | 1 | 25 | |||||||||
|
|
|
|
|
| |||||||
December 31, 2020 | -3 448 | -1 080 | -4 528 | |||||||||
|
|
|
|
|
| |||||||
Allowances | -1 772 | -607 | -2 379 | |||||||||
Write-back on disposals/scrapping | 47 | 404 | 451 | |||||||||
Redeployment | 0 | |||||||||||
Exchange differences | -39 | -39 | ||||||||||
|
|
|
|
|
| |||||||
December 31, 2021 | -5 212 | -1 283 | -6 496 | |||||||||
|
|
|
|
|
| |||||||
Net value in thousands of euros | Real estate property | Others | Total | |||||||||
December 31, 2019 | 10 547 | 927 | 11 474 | |||||||||
December 31, 2020 | 8 834 | 1 039 | 9 873 | |||||||||
December 31, 2021 | 7 648 | 1 006 | 8 654 |
2.5 Current and non-current financial assets
The following is a breakdown of current and non-current financial assets:
December 31, 2021 | December 31, 2020 | |||||||||||||||
in thousands of euros | Non-current financial assets | Current financial assets | Non-current financial assets | Current financial assets | ||||||||||||
Deposits and guarantees | 688 | 485 | ||||||||||||||
Others | 85 | 90 | ||||||||||||||
|
|
|
|
|
|
|
| |||||||||
Total | 773 | 0 | 575 | 0 | ||||||||||||
|
|
|
|
|
|
|
|
2.6 Inventories
The breakdown of Inventories is as follows:
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Inventories of raw materials and active ingredients | 5 041 | 4 772 | ||||||
Inventories of intermediate and finished products | 6 074 | 1 081 | ||||||
Merchandise inventories | 13 469 | 26 663 | ||||||
|
|
|
| |||||
Gross value | 24 585 | 32 516 | ||||||
Provisions for impairment | -1 859 | -974 | ||||||
|
|
|
| |||||
Net value | 22 726 | 31 543 | ||||||
|
|
|
|
28
Financial year 2020:
The increase in the gross value of inventories is mostly attributable to a drop in sales as a result of the health crisis, which has resulted in an increase in stocks.
Other factors support the increase in inventory:
• | Compeed’s market penetration in the United States is lower than projected; |
• | Compeed packaging was modified in Germany, and there remained stocks of the old packaging as of December 31, 2020; |
• | At the start of 2020, the Compeed Cold Sore product was reintroduced to the market; |
• | The Compeed Cold Sore product was reintroduced to the market at the start of 2020; due to delivery delays, products in the “Endocrinology” and “Women’s Health” sectors are back over the safety stock level. |
The inventory impairment applies to both Goods and Finished Goods stocks (mainly 290 thousand euros for Mederma, 371 thousand euros for Compeed, 126 thousand euros for Metopirone and 93 thousand euros for ella).
Financial year 2021:
Improved sales performance, as well as better inventory control and procurement, are primarily responsible for the decrease in the gross value of stocks. As a result, inventory is reduced.
Changes in inventory schedule:
in thousands of euros | Net stock as at 31 December 2020 | Variations in stock | Net final stock as at 31 December 2021 | |||||||||
Raw materials and active ingredients | 4 772 | 268 | 5 041 | |||||||||
Stocks of intermediate products | 930 | 1 399 | 2 329 | |||||||||
Stocks of finished products and goods purchased | 25 841 | -10 484 | 15 357 | |||||||||
|
|
|
|
|
| |||||||
Total | 31 543 | -8 817 | 22 726 | |||||||||
|
|
|
|
|
|
2.7 Trade and other receivables
This item can be analyzed as follows:
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Accounts receivable | 55 003 | 51 322 | ||||||
Provisions for impairment | -1 404 | -2 898 | ||||||
|
|
|
| |||||
Net value | 53 599 | 48 423 | ||||||
|
|
|
|
Financial year 2020:
The change in trade receivables of - 28,202 thousand euros is mainly attributable to the decrease in Compeed and ella sales.
29
The decrease in impairment (- 414 thousand euros) results mainly from:
• | The reversal of the impairment provision for HRA Rare Diseases customers who are handled by our custodian CSP (- 369 thousand euros); |
• | The settlement of invoices received from the Tunisian Pharmacie Centrale from 2016 to 2017 (- 348 thousand euros); |
• | Orient UPO has received payment of invoices for 2019 from its Lebanese partner Union Pharma (- 332 thousand euros); |
• | As a result of the Esmya dispute with Taiwanese partner Orient Europharma (+ 126 thousand euros), an impairment loss was incurred; |
• | As a result of the dispute with the partner Brands 2 Africa (+ 128 thousand euros), an impairment was determined; |
• | An impairment loss was recorded as a result of the late payment of invoices by the partner Brand Solutions Australia (+ 389 thousand euros) at the end of 2019 and February 2020. |
Financial year 2021:
The increase in sales is primarily responsible for the change in trade receivables of + 3,681 thousand euros.
It should be highlighted that the average collection period for receivables has consistently decreased, owing mostly to the HRA Pharma Iberia entity, but also to late payment of invoices from the rare diseases sector’s distributor in the United States.
Trade receivables must be paid within a year.
2.8 Other receivables
Other receivables can be broken down as follows:
in thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Tax receivable | 7 233 | 5 842 | ||||||
Other tax receivables | 2 972 | 274 | ||||||
VAT receivables | 9 213 | 11 479 | ||||||
Suppliers receivables | 1 780 | 1 976 | ||||||
Receivables on disposal of fixed assets | — | — | ||||||
Other operating receivables | 115 | 88 | ||||||
|
|
|
| |||||
Net value | 21 313 | 19 659 | ||||||
|
|
|
|
Financial year 2020:
The VAT adjustment made in 2020 on invoicing for 2018 and 2019 between Laboratoire HRA Pharma and HRA Pharma Deutschland (5,050 thousand euros) and Laboratoire HRA Pharma and HRA Pharma UK (+8,130 thousand euros) is primarily responsible for the change in the VAT item of +8,130 thousand euros (3,142 thousand euros).
Financial year 2021:
The change in “Other tax receivables” is due to a €2 million credit position following the URSSAF’s audit of HRA Pharma France’s pharmaceutical taxes.
30
2.9 Cash and cash equivalents
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Cash | 40 573 | 18 157 | ||||||
Cash in vault | 2 | 6 | ||||||
|
|
|
| |||||
Net value | 40 575 | 18 163 | ||||||
|
|
|
|
Cash and cash equivalents include cash on hand.
Financial year 2020:
We recorded an increase in our cash position of 1.9 M€; this can be explained by the following events:
• | sharp decline in activity (-47% on 2020 EBITDA vs. 2019) offset by good management of our WCR (+€12.7m on 2020); |
• | 20 million: increase in our senior debt to guarantee liquidity following the situation generated by Covid-19; |
• | 8 million: new loan from BPI; |
• | 35 million: repayment of the Revolving Credit Facility (0 RCF debt to date). |
Financial year 2021:
Timing of payment has improved for the Group, with receivables collection periods falling from 90 to 78 days.
2.10 Share capital
Astorg and its co-investors Goldman Sachs Merchant Banking Division control the bulk of the Company’s capital through HERA Lux, the majority shareholder; as of April 1, 2021, the shareholders have changed ownership of their investment in the HRA Pharma Group. Since April 1, 2021, a new holding company has been established in Luxembourg, and the HERA shares have been owned by HRA Newco, which is held by HRA Lux.
This transfer solely affects HERA’s ordinary and preference shares, not the convertible bonds, which remain in the hands of HERA Lux.
The following is the breakdown of the share capital:
Breakdown of share capital | number of ordinary shares | number of preferential shares | total number of shares | Face value | Share capital | |||||||||||||||
December 31, 2019 | 3 815 756 | 32 046 612 | 35 862 368 | 1 | € | 35 862 368 | € | |||||||||||||
December 31, 2020 | 3 815 756 | 32 046 612 | 35 862 368 | 1 | € | 35 862 368 | € | |||||||||||||
December 31, 2021 | 3 815 756 | 32 046 612 | 35 862 368 | 1 | € | 35 862 368 | € |
Ordinary shares
The ordinary shares are classified as equity instruments.
31
Preferential shares
Preferential shares are classified as equity instruments.
Preferential shares entitle their holders to a cumulative preferential dividend subject to the existence of distributable cash and the decision of the Company’s general meeting to distribute preferential dividends.
2.10.1 Share-based payments - Stock options and free shares
As of December 31, 2021, the instruments issued are as follows:
Type of instrument | Free Ordinary Shares | Free Preferential Shares | Stock Option | Total | ||||||||||||
Number | 16 912 | 269 442 | — | 286 354 |
Stock-based compensation instruments are recognized as employee benefits expense, with a corresponding entry to equity, at the fair value of the instruments awarded at the grant date, in accordance with IFRS 2. The cost of this investment is spread out throughout the vesting period.
No movement has been recorded in 2021 on these plans.
Valuation of share-based payment transactions to be integrated:
The Black-Scholes option pricing model is used to determine the fair value of stock options issued to employees.
The share price on the valuation date, the instrument’s exercise price, estimated volatility, the weighted average life of the instruments, expected dividends, and the risk-free interest rate are all inputs to the valuation (based on government bonds). The transaction’s service and performance conditions, which are not market factors, are not taken into account for determining fair value.
2.10.2 Non-controlling interests
In April 2020, Laboratoire HRA Pharma signed an agreement with Profex, a Chinese partner, for the development of Compeed and Mederma product marketing in China. According to these agreements, Profex owns 33% of HRA Pharma Hong Kong’s capital, while Laboratoire HRA Pharma owns the remaining 67%.
Profex and Laboratoire HRA Pharma have a shareholders’ agreement that gives Laboratoire HRA Pharma a call option on Profex’s shares. This call option can be exercised in a variety of circumstances, including a change of control of the Company, and at different valuations depending on the results of the activities in China and when the option is executed.
Profex also has the right to sell its shares to Laboratoire HRA Pharma in exceptional circumstances, such as if Laboratoire HRA is intentionally in breach of its own contractual commitments. The price at which this right can be exercised varies based on the outcomes of relevant operations in China and the date on which this right is exercised, if at all.
In light of the foregoing, the Group concludes Profex’s entitlement to sell its shares to Laboratoire HRA Pharma is contingent on factors that are wholly within the Group’s control. At the balance sheet date, the Group had not recognized any financial liability related to Profex’s right to sell its shares to Laboratoire HRA Pharma.
32
2.11 Provisions for employee benefits
Changes in provisions for employee benefits over the two financial periods were as follows:
In thousands of euros | Provisions for staff benefits | |||
December 31, 2019 | 1 914 | |||
|
| |||
Expenses | 507 | |||
Reclassification | ||||
Unused reversals | -154 | |||
|
| |||
December 31, 2020 | 2 266 | |||
|
| |||
Expenses | 311 | |||
Reclassification | ||||
Unused reversals | -137 | |||
|
| |||
December 31, 2021 | 2 441 | |||
|
|
The item Provisions for employee benefits breaks down as follows:
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
France | 2 441 | 2 266 | ||||||
|
|
|
| |||||
Total | 2 441 | 2 266 | ||||||
|
|
|
|
Employee benefits provisions concern the French companies Héra S.A.S., Laboratoire HRA Pharma S.A.S., HRA Pharma France S.A.S., and HRA Pharma Rare Diseases S.A.S. They primarily pertain to provisions for retirement indemnities for Group employees.
At this time, no funds have been set up to satisfy these obligations.
The following are the primary actuarial assumptions that were used:
France | December 31, 2021 | December 31, 2020 | ||||||
Discount rate | 0,80% | 0,35% | ||||||
Gross average growth rate of payroll inflation | 3,00% | 1,75% | ||||||
Average remaining working life of employees (in years) | 23,6 | 23,8 | ||||||
Employer’s social security rates | 45% | 45% |
The present value of the commitment is broken down as follows:
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Total current value of liabilities at the beginning of the year | 2 266 | 1 914 | ||||||
|
|
|
| |||||
Current service cost | 407 | 556 | ||||||
Interest expense | 10 | 12 | ||||||
Actuarial gains and losses (Change in method - Equity) | -397 | — | ||||||
Actuarial gains and losses | 154 | -216 | ||||||
|
|
|
| |||||
Total current value of commitments at year-end | 2 441 | 2 266 | ||||||
|
|
|
|
The cost over each financial year can be broken down as follows:
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Current service cost | 407 | 556 | ||||||
Interest expense | 10 | 12 | ||||||
|
|
|
| |||||
Cost for the period | 418 | 568 | ||||||
|
|
|
|
33
No social security contributions have been paid for the years 2020 and 2021.
2.12 Provisions
Changes in provisions during the two years were as follows:
In thousands of euros | Provisions for contingencies | |||
December 31, 2019 | 1 434 | |||
|
| |||
Expenses | ||||
Reclassification | ||||
Reversals used | -540 | |||
Unused reversals | -559 | |||
|
| |||
December 31, 2020 | 335 | |||
|
| |||
Dotations | 781 | |||
Reclassement | ||||
Reversals used | -212 | |||
Unused reversals | -83 | |||
|
| |||
December 31, 2021 | 821 | |||
|
|
Financial year 2020:
A reversal of the provision in the amount of 648 thousand euros was recorded following the resolution of the disagreement with Perrigo, the Portuguese distributor; the agreement with the Tax Authorities on the tax audit resulted in the reversal of the provision created in 2019 in 2020. (383 thousand euros).
Financial year 2021:
For the research tax credit, a provision of 559,000 euros has been made for tax risks related to Laboratoire HRA Pharma’s tax audit for the years 2014 to 2016.
A provision for litigation with our partner SANOVA has also been recognized for the year 2021 in the amount of 150 thousand euros.
2.12.1 Provisions for tax liabilities
Several audits of some Group firms’ finances took place in 2021 or proceeded throughout the year:
• | Firstly, two audits were carried out by URSSAF on the social security charges of Hera and HRA Pharma Rare Diseases. These two audits resulted in adjustments of less than 50 thousand euros. |
• | Laboratoire HRA Pharma underwent a tax examination, which resulted in a correction that had no impact on the Group’s consolidated finances. |
• | A URSSAF audit of the pharmaceutical taxes owed by HRA Pharma France results in a repayment of 2,360 thousand euros in favor of the company. |
• | Laboratoire HRA Pharma has been in a dispute with the French tax authorities since May 2017 as a result of an audit covering the period from January 1, 2014 to March 31, 2016. The corporation was contesting an adjustment of €1,924 thousand and €1,059 thousand, respectively, relating to the imposition of withholding tax on sums received as salary for two employees and on the research tax credit. |
34
On April 10, 2020, HSBC bank issued a 1,924,000 deposit for direct taxes to guarantee tax payment.
The corporation is still in litigation with the Administrative Court about withholding tax, but the French tax authorities have agreed to a significant reduction in the amount claimed for research tax credit to 559 thousand euros after a hearing before the research tax credit committee. The company has agreed to accept this adjustment because it expects to recover more than 330 thousand euros over the fiscal year from April 1, 2016 to December 31, 2016.
• | An audit of HRA Pharma Iberia’s general accounting for the years 2017, 2018, 2019, and 2020 is still underway. |
The Spanish government has not made any claims as of today.
2.13 Borrowings and financial debts
The breakdown between current and non-current financial liabilities is shown below:
December 31, 2021 | December 31, 2020 | |||||||||||||||||||||||||||||||
In thousands of euros | Portion due within one year | Portion due between 1 and 5 years | Portion due after 5 years | Total | Portion due within one year | Portion due between 1 and 5 years | Portion due after 5 years | Total | ||||||||||||||||||||||||
Convertible bonds and interest on convertible bonds | 303 226 | 53 177 | 356 403 | 323 263 | 323 263 | |||||||||||||||||||||||||||
Bonds and interest on bonds | 486 276 | 486 276 | 484 129 | 484 129 | ||||||||||||||||||||||||||||
Other bank loans | 13 | 13 | 8 000 | 8 000 | ||||||||||||||||||||||||||||
Revolving credit | 0 | 0 | ||||||||||||||||||||||||||||||
Accrued interest on other bank loans | 0 | 21 | 21 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||
Loans and financial debts | 0 | 789 515 | 53 177 | 842 692 | 21 | 492 129 | 323 263 | 815 414 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible obligations
Proceeds from the convertible bond issue (244,232,178 bonds with a par value of €1 issued on February 18, 2016 and 99,564,440 bonds with a par value of €1 issued on September 20, 2017) amounted to €343.8 million.
The convertible bonds subscribed in 2016 and 2017, were partially redeemed in fiscal 2019, for €52.6 million and €60.4 million respectively.
At the end of the two fiscal years, the amounts of these convertible bonds were €177.1 million and €35.8 million respectively. Interest on convertible bonds are capitalized and amount to €143.5 million.
Bonds
This item corresponds to four bonds: two issued on September 20, 2017 for a term of 7 years and bearing interest at a 3-month Euribor + margin of 3.5%, for amounts net of transaction costs of €80.7 million and €301 million, a third issued on March 14, 2018 for an amount net of transaction costs of €30.8 million, and a fourth issued on June 27, 2019 for a term of 6 years and 1 month and bearing interest at a 3-month Euribor + margin of 3.5%, for an amount net of transaction costs of €45.7 million.
On March 26, 2020, an additional loan of €20 million was secured for a term of 4 years and 6 months, with interest calculated at 3-month Euribor + 3.5% margin for a net value of €19.6 million.
Various hedging contracts have been drawn up by the company to cover the 3-month Euribor until December 2022.
Covenants are in place for these loans.
These obligations were fulfilled on December 31, 2021. For the next 12 months, the company expects to fulfill them.
35
Hedging Instruments
The Company and HRA Pharma have entered into interest rate cap agreements with Société Générale and Goldman Sachs to hedge against rising interest rates on the interest flows linked with its variable rate financing.
Portions of the Goldman Sachs hedges will expire at the end of June 2020 and again in June 2021.
Credit Revolving
In 2017, the Group established a €40 million revolving credit facility, which was increased to €60 million in June 2019; since then, the Group has made various withdrawals and repayments.
The Group had no withdrawals on this credit at the end of the two fiscal years and a financing reserve of €60 million.
Other loans
On September 28, 2020, a new loan (Club BPI) for €8 million was signed with the partner BPI for a three-year term. The conditions are as follows: the interest rate is 3-month Euribor+1.1%, plus a commitment fee of 0.95%.
This loan was fully repaid and the contract terminated on December 31, 2021 without penalty.
Currency hedging
HRA Pharma has also hedged against potential foreign exchange risks by entering into forward exchange contracts on the GBP and USD currencies with HSBC and Société Générale banks.
2.13.1 Changes in financial liabilities
In thousands of euros | Convertible bonds | Bond issues | Borrowing from credit institutions | Interest accrued on borrowing | Total | |||||||||||||||
December 31, 2019 | 208 858 | 462 429 | 35 000 | 84 377 | 790 664 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
New loans | 20 000 | 8 000 | 28 213 | 56 213 | ||||||||||||||||
Changes in fair value | 1 838 | 1 700 | 3 538 | |||||||||||||||||
Reclassification | 0 | |||||||||||||||||||
Repayments | -35 000 | -35 000 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
December 31, 2020 | 210 695 | 484 129 | 8 000 | 112 590 | 815 414 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
New loans | 10 000 | 30 923 | 40 923 | |||||||||||||||||
Changes in fair value | 2 230 | 2 147 | 4 377 | |||||||||||||||||
Reclassification | 0 | |||||||||||||||||||
Repayments | -18 000 | -22 | -18 022 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
December 31, 2021 | 212 925 | 486 276 | 0 | 143 491 | 842 692 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
The initial terms of the loans contracted with credit institutions are presented below:
Bank | Date of signature of the loan agreement | Nominal amount (in €) | Term | Reference rate | ||||
Convertible Bonds | févr-16 | 244 232 178 | 10 years | 9% | ||||
Convertible Bonds | sept-17 | 99 564 440 | 10 years | 9% | ||||
Senior Bond | sept-17 | 83 180 811 | 7 years | Euribor with a margin of 3.5% | ||||
Senior Bond | sept-17 | 310 819 189 | 7 years | Euribor with a margin of 3.5%. | ||||
Senior Bond | mars-18 | 31000 000 | 78 months | Euribor with a margin of 3.5%. | ||||
Second Lien | juin-19 | 48 000 000 | 73 months | Euribor with a margin of 8,25% | ||||
Senior Bond | mars-20 | 20 000 000 | 54 months | Euribor with a margin of 3,5% | ||||
BPI Club Loan | sept-20 | 8 000 000 | 36 months | Euribor with a margin of 1,1% |
36
Loans can be repaid early without penalty at the company’s choice; this was the case with the €8 million BPI loan, which was repaid early on December 15, 2021.
2.14 Lease liabilities
The breakdown between current and non-current rental liabilities is as follows:
December 31, 2021 | December 31, 2020 | |||||||||||||||||||||||||||||||
In thousands of euros | Portion due within one year | Portion due between 1 and 5 years | Portion due after 5 years | Total | Portion due within one year | Portion due between 1 and 5 years | Portion due after 5 years | Total | ||||||||||||||||||||||||
Leasehold debts - Real estate | 1 827 | 5 429 | 1 441 | 8 697 | 1 772 | 5 512 | 2 730 | 10 014 | ||||||||||||||||||||||||
Leasehold debts - Movable property | 514 | 489 | 1 002 | 524 | 517 | 0 | 1 040 | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||
Leasehold debts | 2 341 | 5 917 | 1 441 | 9 699 | 2 296 | 6 029 | 2 730 | 11 055 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Low-value asset contracts and short-term contracts have no significant costs.
2.15 Other debts
December 31, 2021 | December 31, 2020 | |||||||||||||||||||||||
in thousands of euros | Current portion | Non-current portion | Total | Current portion | Non-current portion | Total | ||||||||||||||||||
Liabilities on fixed assets | 3 298 | 3 298 | — | 0 | ||||||||||||||||||||
Payables to employees | 8 920 | 8 920 | 5 529 | 5 529 | ||||||||||||||||||||
Social security debts | 1 324 | 1 324 | 1 239 | 1 239 | ||||||||||||||||||||
Current tax liability | 147 | 147 | 575 | 575 | ||||||||||||||||||||
Other tax liabilities | 463 | 463 | 696 | 696 | ||||||||||||||||||||
Collected VAT | 4 266 | 4 266 | 4 610 | 4 610 | ||||||||||||||||||||
Customers - Credit notes to be issued | 10 197 | 10 197 | 6 372 | 6 372 | ||||||||||||||||||||
Other liabilities | 400 | 400 | 413 | 413 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total | 29 015 | 0 | 29 015 | 19 434 | 0 | 19 434 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
The accrual for paid vacations and bonuses, as well as the accompanying social security costs, profit-sharing, and donations owed to various social organizations, are all included in the social security liabilities.
Financial year 2020:
Credit notes to be issued on French companies include the partner Céolia for the product Metopirone Japan (927 thousand euros), the partner Takeda for the products Norlevo and ella Sweden, Denmark and Norway (68 thousand euros), the product Ketoconazole (227 thousand euros) and for the product Compeed (547 thousand euros). Credit notes to be issued on overseas subsidiaries mostly concern the goods ella (1,905 thousand euros, including 1,579 thousand euros in the United States), Mederma US (1,367 thousand euros), and Compeed (827 thousand euros of which 726 thousand euros in the UK).
During the first half of 2019, an agreement was reached with the partner Preglem (Gédéon Richter Group) that resulted in the latter paying 3,561 thousand euros in royalties on previous years’ sales made by Preglem, particularly in France, the amount of which was in dispute with the French government. Preglem notified us that the dispute had been settled with a result in favor of the French State and asked us to issue a credit note of 2,468 thousand euros as a reduction of the amount received following the above-mentioned agreement. This credit note was issued in the first half of 2020, which explains in part the significant decrease in the item “Trade accounts receivable - Credit notes”.
Following Esmya’s exit from the market, it was deemed that the €7 million residual debt, which represented the last component of the royalty for the license of Preglem’s know-how, could no longer be offset by milestone payments.
37
As a result, the €7 million debt was eliminated after Preglem-Richter confirmed the foregoing in a letter dated November 17, 2020.
Financial year 2021:
The increase in “Customers - Credit notes to be issued” is due to a change in the classification of the rebates on sales from “Trade accounts payable” to this item.
2.16 Deferred income
December 31, 2021 | December 31, 2020 | |||||||||||||||||||||||
in thousands of euros | Current portion | Non-current portion | Total | Current portion | Non-current portion | Total | ||||||||||||||||||
Deferred income / Downpayments | 119 | 565 | 684 | 106 | 462 | 568 | ||||||||||||||||||
Deferred income relating to the research tax credit for capitalized expenses | 18 | 101 | 119 | 85 | 163 | 248 | ||||||||||||||||||
Other | 0 | 0 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total deferred income | 137 | 666 | 803 | 191 | 625 | 816 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Financial year 2020:
Advance payments received by the Group in relation of license agreements, but whose recognition is deferred, totaled 568 thousand euros as of December 31, 2020.
Financial year 2021:
Advance payments received by the Group in relation of license agreements, but whose recognition is deferred, totaled 684 thousand euros as of December 31, 2021.
in thousands of euros | Beginning of the year | Receipts | Revenue recognized during the period |
| ||||||||||||
December 31, 2019 | 4 653 | -3 909 | 744 | |||||||||||||
December 31, 2020 | 744 | -176 | 568 | |||||||||||||
December 31, 2021 | 568 | 273 | -158 | 684 |
Financial year 2020:
As of December 31, 2020, no payments under license agreements were received as revenue.
As of December 31, 2020, the amount of “downpayments” recorded as revenue is 176 thousand euros.
Financial year 2021:
A total of 273 thousand euro payments has been received under license agreements signed in 2021.
At December 31, 2021, the amount of “downpayments” recorded as revenue was 158 thousand euros.
38
2.17 Fair value table
The following table presents the book values and fair values of financial assets and liabilities and their level in the fair value hierarchy:
Balance sheet value at 12/31/2021 | Fair value | Level 1 - stock market price | Level 2 - observable data | Level 3 - unobservable data | ||||||||||||||||
Financial assets measured at amortized cost | ||||||||||||||||||||
Trade and other receivables | 53 599 | 53 599 | 53 599 | |||||||||||||||||
Financial assets measured at fair value | ||||||||||||||||||||
Financial assets | 782 | 782 | 782 | |||||||||||||||||
Derivative asset instruments | 63 | 63 | 63 | |||||||||||||||||
Cash and cash equivalents | 40 575 | 40 575 | 40 575 | |||||||||||||||||
Financial liabilities measured at amortized cost | ||||||||||||||||||||
Borrowings and financial debts | 842 692 | 963 284 | 963 284 | |||||||||||||||||
Financial liabilities measured at fair value | ||||||||||||||||||||
Derivative liability instruments | 952 | 952 | 952 |
3 NOTES TO THE STATEMENT OF PROFIT AND LOSS
3.1 Revenue from ordinary activities
The breakdown of revenues from ordinary activities between the two areas is as follows:
December 31, 2021 | December 31, 2020 | |||||||||||||||||||||||||||||||
In thousands of euros | CHC | RX | Services | Total | CHC | RX | Services | Total | ||||||||||||||||||||||||
Turnover | 212 127 | 43 630 | 166 | 255 923 | 156 852 | 44 279 | 411 | 201 542 | ||||||||||||||||||||||||
Royalties and license fees | 826 | -221 | 605 | 545 | 839 | 1 384 | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||||
Total Revenue from Ordinary Activities | 212 954 | 43 409 | 166 | 256 529 | 157 397 | 45 118 | 411 | 202 926 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial year 2020:
The Group’s revenue from ordinary activities, which is made up 99% of pharmaceutical items, declined by 20% in fiscal year 2020 as a result of the current health crisis.
Compeed (- 39%) and ella (- 28%), both from the Consumer Healthcare segment, were the most impacted.
On the other hand, the Metopirone product, in the segment “RX” experienced substantial growth (+ 33%), driven primarily by the North America zone (+1,446 thousand euros, or + 59%) and the Asia zone (+ 445 thousand euros, or + 18%).
Financial year 2021:
Despite a context still affected by the crisis linked to the Covid-19 pandemic, the Group’s revenue from ordinary activities, 99.8% of which is made up of pharmaceutical products, increased by 27% in the 2021 financial year.
We saw a rebound in activity, with sales of Compeed products up 48.2%, the “Women Health” section up 23.5%, and Mederma products up 25.7%.
While Covid-19 had no effect on the “rare diseases” section in 2020, it did in 2021, when many patients were unable to enter hospitals due to the priority given to Covid-19.
39
3.2 Operating expenses
Financial year 2020:
The “Covid-19” global pandemic had a huge impact on the company.
The Group has reduced its variable costs, particularly promotional expenses, in order to mitigate the impact of Covid-19 on its profitability.
The significance of “research and development costs” has stayed unchanged.
The costs of management and support services, as well as all Group infrastructure costs, are included in general and administrative expenses.
Financial year 2021:
The global “Covid-19” pandemic has had an impact on the business. The Group has attempted to mitigate the impact of Covid-19 on its profitability by slashing variable costs, particularly promotional costs.
The Group’s operating expenses (excluding “Other Operating Expenses and Revenues”) to Ordinary Revenue ratio has decreased slightly (47.1% vs. 49.3%), owing to lower “Marketing and sales expenses” (30.3% vs. 31.1%) and “Research and development expenses” (3.5% vs. 4.6%).
While significant promotional expenses were spent, such as those for the launch of Hana in the United Kingdom or the investment in TV commercials in the United States for Compeed and Méderma, the “Marketing and sales expenses” item has a ratio of 30.3% compared to the Ordinary Revenue, i.e. -2.5% compared to December 2020.
The costs of management and support services, as well as all of the Group’s infrastructure costs, are included in general and administrative expenses.
As a result of various tax audits, there was an increase in consultation fees.
3.2.1 Staff costs
The personnel expenses recorded in the income statement include the following items:
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Wages and salaries | 21 902 | 20 864 | ||||||
Social security costs | 10 264 | 9 691 | ||||||
Social benefits (bonuses, annual leave, benefits....) | 5 122 | 4 406 | ||||||
Retirement provision | 496 | 556 | ||||||
Profit-sharing - Incentives | 1 225 | 116 | ||||||
|
|
|
| |||||
Total | 39 009 | 35 634 | ||||||
|
|
|
|
Bonuses for 2021 were accrued on a 100% basis, opposed to 50% in 2020.
40
The income statement breaks down these expenses as follows:
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Cost of sales | 3 876 | 3 671 | ||||||
Marketing and sales costs | 13 206 | 11 443 | ||||||
Administrative costs | 17 213 | 14 942 | ||||||
Research and development costs | 4 657 | 4 224 | ||||||
Other operating costs | 57 | 338 | ||||||
Non-routine costs (*) | 1 | 1 016 | ||||||
|
|
|
| |||||
Total | 39 009 | 35 634 | ||||||
|
|
|
|
(*) | In fiscal year 2020, we find mainly salaries + employer’s contributions (159 thousand euros), bonuses + employer’s contributions (475 thousand euros) and vacation pay + employer’s contributions (336 thousand euros). |
3.2.2 Headcount
The Group had 250 employees at December 31, 2021, compared with 240 at December 31, 2020. The number of employees at the end of the years is broken down as follows:
December 31, 2021 | December 31, 2020 | |||||||
Cost of sales | 30 | 31 | ||||||
Marketing and selling expenses | 89 | 78 | ||||||
Administrative costs | 97 | 97 | ||||||
Research and development costs | 33 | 34 | ||||||
|
|
|
| |||||
Total | 250 | 240 | ||||||
|
|
|
|
It should be mentioned that a new profit-sharing agreement for the period of January 1, 2020 to December 31, 2022 was signed on July 27, 2020 at the UES level, which includes Laboratoire HRA Pharma, HRA Pharma France, and HRA Pharma Rare Diseases.
On July 28, 2020, a new agreement was reached for Héra, also for a three-year period.
3.3 Other operating income and expenses
Financial year 2020:
Other operating income and expenses (- €9.6 million) correspond mainly to:
Operating income from “commercial activities”:
• | taxes (totaling €1.2 million) (including the Safeguard Clause Tax, the Social Solidarity Contribution, the Tax on the Promotion of Medical Devices, and the New Contribution Tax on Sales); |
• | realized foreign exchange gains and losses on trade receivables and payables (expense of €0.7 million) and unrealized foreign exchange gains and losses (expense of €0.6 million); |
• | Following the signing of a contract with SWIXX, the Compeed product distributor in Russia, €1.25 million will be paid to them (50%in December 2020 and 50% in July 2021) to help their advertising effort and, following Covid-19, to destroy any obsolete stock they may have. |
Operating income related to “general expenses”:
• | depreciation of leases due to the application of IFRS 16 (amount of €2.4 million); |
• | taxes (including the Territorial Economic Contribution, i.e. a total expense of €1.3 million). |
41
Financial year 2021:
Other operating income and expenses (- €0,3 million) correspond mainly to:
Operating income from “commercial activities”:
• | taxes (totaling €0.5 million) (including the Safeguard Clause Tax, the Social Solidarity Contribution, the Tax on the Promotion of Medical Devices, and the New Contribution Tax on Sales); |
• | realized foreign exchange gains and losses on trade receivables and payables (revenue of €0.5 million) and unrealized foreign exchange gains and losses (revenue of €0.3 million); |
• | Adjustments to taxes on the promotion of medical devices paid from 2018 to 2020 (total revenue of €2.4 million). |
Operating income related to “general expenses”:
• | depreciation of leases due to the application of IFRS 16 (amount of €2.4 million); |
• | Government assistance related to the impact of Covid-19 on the German subsidiary’s business resulted in a 545 thousand euros profit; |
• | taxes (including the Territorial Economic Contribution, i.e. a total expense of €0.8 million). |
3.4 Other income and expenses
Financial year 2020:
Other income and expenses (-€16.3 million) primarily consist of:
• | restructuring costs (-€2.3 million); |
• | cancellation of Preglem debt following the withdrawal of Esmya from the market (+€7 million); |
• | amortization of revalued intangible assets (€3.8 million); |
• | depreciation of Esmya assets (€1.2 million); |
• | disposal of Ellis fixed assets (-€7.9 million); |
• | disposal of UPSI fixed assets (-€0.4 million); |
• | compensation paid to the Greek partner Arriani for breach of contract (€1.5 million); |
• | costs related to the Harvey operation (€0.5 million); |
• | costs generated by the integration of the Compeed product (€1.2 million); |
• | costs generated by the integration of the Mederma product (€0.7 million); |
• | provision for customer impairment on Downpayment Esmya (€0.75 million); |
• | disposal of revalued Mederma inventories (€0.9 million). |
Financial year 2021:
Other income and expenses (-€4.6 million) primarily consist of:
• | amortization of intangible assets acquired as part of a business combination (-€1.2 million); |
• | costs related to the PERRIGO transaction (€-1.2 million) |
• | disposal of revalued Mederma inventories (-€0.4 million); |
• | payment fraud of the Spanish supplier UM (-€0.5 million); |
42
• | provisions for litigation (-€0.7 million); |
• | provision for tax risk (-€0.5 million). |
3.5 Financial result
Financial revenue and expenses can be broken down as shown in the table below:
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Foreign exchange losses | -1 879 | -1 101 | ||||||
Interest expense on loans | -55 927 | -53 395 | ||||||
Financial expenses related to leases | -166 | -194 | ||||||
Currency hedging | -1 210 | — | ||||||
Other financial expenses | -378 | -498 | ||||||
|
|
|
| |||||
Total financial expenses | -59 559 | -55 188 | ||||||
|
|
|
| |||||
Income from financial assets and cash investments | 2 | — | ||||||
Foreign exchange gains | 2 022 | 787 | ||||||
Disposal of financial liabilities related to leases | 11 | 12 | ||||||
Currency hedging | — | 446 | ||||||
Other financial revenues | 170 | 6 | ||||||
|
|
|
| |||||
Total Financial Revenues | 2 205 | 1 251 | ||||||
|
|
|
| |||||
Total financial income | -57 354 | -53 937 | ||||||
|
|
|
|
Foreign exchange gains and losses relate to financial transactions.
Financial year 2020:
Interest on convertible bonds (€30.1 million), bonds (€21.8 million), and the revolving credit facility (€1.4 million) make up the bulk of net financial income.
Financial year 2021:
Net financial income consists mainly of interest on convertible bonds (€33.1 million), on bonds (€22.0 million) and on the revolving credit facility (€0.7 million).
3.6 Income tax
3.6.1 Breakdown of tax expense
In thousands of euros | December 31, 2021 | 31 décembre 2020 | ||||||
Taxes payable | -250 | -303 | ||||||
Deferred taxes | -2 622 | 6 741 | ||||||
|
|
|
| |||||
Total | -2 872 | 6 439 | ||||||
|
|
|
|
43
Under current French regulations, tax losses can be carried forward indefinitely.
3.6.2 Reconciliation between actual and notional tax
In thousands of euros | December 31, 2021 | 31 décembre 2020 | ||||||
Pre-tax income of consolidated companies | -221 | -33 648 | ||||||
Income tax rate applicable to the parent company | 27,37 | % | 28,92 | % | ||||
|
|
|
| |||||
Theoretical tax (expense)/ income | 60 | 9 731 | ||||||
|
|
|
| |||||
Tax rate discrepancies between countries | -3 036 | -4 093 | ||||||
Ongoing variations | 335 | 47 | ||||||
Non-taxable tax credits | 603 | 566 | ||||||
Recognition of tax loss carryforwards | -60 | 232 | ||||||
Non-recognition of losses carried forward | -240 | -11 | ||||||
Other | -535 | -33 | ||||||
|
|
|
| |||||
Actual income tax (expense)/income | -2 872 | 6 439 | ||||||
|
|
|
| |||||
Effective tax rate | -1300 | % | 19,1 | % |
3.6.3 Breakdown of deferred tax assets and liabilities
In thousands of euros | December 31, 2021 | December 31, 2020 | ||||||
Deferred tax assets: | ||||||||
Provisions for employee benefits | 631 | 585 | ||||||
Inventory margins | 7 030 | 11 578 | ||||||
Deferred revenue | 178 | 146 | ||||||
Deferred tax assets/losses carried forward | 8 417 | 8 476 | ||||||
Tax / accounting variances | 668 | 203 | ||||||
Exclusivity rights related to the Compeed acquisition | 13 103 | 13 103 | ||||||
Restatement of fees related to the acquisition of Lysodren | 90 | 90 | ||||||
Restatement of fees related to the Méderma acquisition | 102 | 102 | ||||||
Valuation of CAPs - Interest rate hedging | 43 | 191 | ||||||
Valuation of CAPs - Currency hedging | 260 | — | ||||||
Lease agreements | 97 | 85 | ||||||
Various | — | 18 | ||||||
|
|
|
| |||||
Total deferred tax assets in the balance sheet | 30 618 | 34 577 | ||||||
|
|
|
| |||||
Deferred tax liabilities: | ||||||||
Lease agreements | -4 | -1 | ||||||
PPA (Purchase Price Allocation) - Rebranding Compeed | -92 902 | -92 902 | ||||||
PPA - Revaluation of fixed assets | -958 | -1 297 | ||||||
PPA - Revaluation of Lysodren rights | -9 276 | -9 276 | ||||||
PPA - Revaluation of Méderma brands | -20 503 | -20 503 | ||||||
PPA - Revaluation of Méderma stocks | — | -136 | ||||||
Discounting of the Convertible Bonds | -3 689 | -4 299 | ||||||
Bond issue - effective interest rate calculation | -175 | -157 | ||||||
Valuation of CAPs - Interest rate hedging | — | -11 | ||||||
Valuation of CAPs - Currency hedging | — | -75 | ||||||
|
|
|
| |||||
Total deferred tax liabilities in the balance sheet - Published | -127 508 | -128 658 | ||||||
|
|
|
| |||||
Net deferred taxes | -96 889 | -94 081 | ||||||
|
|
|
|
44
3.7 Earnings per share
3.7.1 Basic earnings per share
The result attributable to equity holders and a weighted average number of shares outstanding over the two years are used to compute basic earnings per share.
December 31, 2021 | December 31, 2020 | |||||||
Net income available to shareholders (in thousands of euros) | -3 166 | -27 241 | ||||||
Weighted average number of shares issued during | 35 862 368 | 35 862 368 | ||||||
Earnings per share | -0,09 | -0,76 |
3.7.2 Diluted earnings per share
Diluted earnings per share are calculated on the basis of earnings attributable to equity holders and a weighted average number of ordinary shares outstanding, adjusted for the effects of all potential dilutive shares.
Instruments giving deferred rights to capital (Free Shares, SO or BSPCE) are considered to be anti-dilutive as they result in an increase in earnings per share from continuing operations. Thus, the diluted earnings per share are identical to the basic earnings per share.
4 RELATED PARTIES
Transactions with key executives, directors, supervisory board members and strategic committee members:
Financial year 2020:
In thousands of euros | Related companies | December 31, 2020 | ||||
Agreements authorized by the company’s General Meeting of May 24, 2012 | ||||||
Contribution to the HRA Pharma Foundation | 150 | |||||
Scientific Board | André Ulmann, Chairman of the Strategic Committee of the company and Director of Cemag | 100 | ||||
Agreements authorized by the general meeting of the company on July 1, 2016 | ||||||
Strategic advisory services to the Supervisory Board of Hera | David Colpman, Member of the Supervisory Board and Director of Consulting Colpman Ltd | 101 |
Financial year 2021:
In thousands of euros | Related companies | December 31, 2021 | ||||
Agreements authorized by the company’s General Meeting of May 24, 2012 | ||||||
Contribution to the HRA Pharma Foundation | 30 | |||||
Scientific Board | André Ulmann, Chairman of the Strategic Committee of the company and Director of Cemag | 100 | ||||
Agreements authorized by the general meeting of the company on July 1, 2016 | ||||||
Strategic advisory services to the Supervisory Board of Hera | David Colpman, Member of the Supervisory Board and Director of Consulting Colpman Ltd | 25 |
45
Total remuneration of Hera’s management team:
Financial year 2020:
The total remuneration of the Hera Executive Leadership Team was 2 795 thousand euros. This broke down as 2 116 thousand euros in fixed compensation, 418 thousand euros in variable compensation and 261 thousand euros in various benefits in kind.
Financial year 2021:
The total remuneration of the Hera Executive Leadership Team was 3 269 thousand euros. This broke down as 2 158 thousand euros in fixed compensation, 850 thousand euros in variable compensation and 261 thousand euros in various benefits in kind.
5 LITIGATION
There are no pending litigations that are anticipated to have a major impact on the financial statements for the two financial years, other than those for which provisions have been made or that are stated in the notes to the financial accounts.
6 OFF-BALANCE SHEET COMMITMENTS
• | Héra and its subsidiary Laboratoire HRA Pharma have entered into a number of loans for an amount of €473 million and to secure these loans, Pledge Agreements were executed on September 20, 2017 relating to: |
• | shares of Laboratoire HRA Pharma held by Héra; |
• | intra-group receivables |
• | Similarly, and still as a guarantee, Laboratoire HRA Pharma has entered into pledge agreements relating to: |
• | its bank accounts; |
• | the shares it holds in HRA Pharma France. |
• | In the context of the partial transfer of assets relating to the “endocrinology” sector from Laboratoire HRA Pharma to HRA Pharma Rare Diseases, Laboratoire HRA Pharma has entered into pledge agreements relating to: |
• | its bank accounts; |
• | the shares it holds in HRA Rare Diseases. |
• | A pledge agreement for the balance of the 3rd rank bank accounts was entered into on March 26, 2020 between HRA Pharma Rare Diseases and HSBC Corporate Trustee Company (UK). |
46
7 FINANCIAL RISK MANAGEMENT
The Group is exposed to the following risks related to the use of financial instruments:
Credit risk
The risk of financial loss to the Group if a client or counterparty to a financial instrument fails to meet its contractual commitments is referred to as credit risk. Trade receivables and marketable securities are the main sources of this risk.
Liquidity risk
Liquidity risk refers to the possibility that the Group will have difficulty meeting its obligations when they become due. The Group’s strategy to managing liquidity risk is to ensure that, as far as feasible, it will always have enough liquidity to cover its liabilities when they are due, whether under normal or stressed conditions, without incurring unacceptable losses or harming its reputation.
The Group makes sure it has enough cash and bank accounts to cover its short-term needs.
The accounts have been prepared on a going concern basis.
Market risk
Market risk refers to the possibility that changes in market prices, such as foreign exchange rates, interest rates, and equity instrument prices, will have an impact on the Group’s earnings or the value of its financial assets. The goal of market risk management is to keep market risk exposures within acceptable bounds while maximizing the risk/reward trade-off.
Foreign exchange risk
The Group’s foreign exchange risk is reduced because research and development costs are incurred in the same currencies (USD, Euro) as the expected revenue streams (US and EU territory).
HRA Pharma has also hedged against foreign exchange risks by entering into forward exchange contracts on the GBP with HSBC bank.
Interest rate risk
The group is not significantly exposed to interest rate risk insofar as so-called “cap” hedging instruments have been contracted since 2017 at the time of the acquisition of the Compeed product portfolio.
Capital risk
The Company has the required resources to finance its activities as part of its capital management strategy, and it has no intention of exposing its shareholders to an undue dilution risk.
8 SUBSEQUENT EVENTS
On February 24, 2022, Russia, supported by Belarus, invaded Ukraine. Following this attack, a number of countries have declared sanctions against both Russia and Belarus and various Russian and Belarusian individuals and businesses. Access to the SWIFT international banking system has been suspended as part of these restrictions.
With the exception of ownership of certain trademarks and product registrations in these countries that have not been allocated a value in the Group’s accounts, the Group owns no assets in these countries and has no employees.
In 2021, the Group generated revenues of 2,305 thousand euros and an operating profit of almost 1,000 thousand euros in Russia. These results are generated exclusively by the Compeed brand. The Compeed brand is distributed in Russia by a Swiss company and all invoices are in euros. This distributor and its shareholders are not mentioned on any sanctions lists. The Group has no activity in Ukraine or in Belarus. The balance of receivables outstanding from this distributor at December 31 was 157 thousand euros.
47
Thus, the Group has no risk on the valuation of its assets and limited exposure on its revenues.
9 AUDITORS’ FEES
The fees paid to the Group’s statutory auditors amounted to:
Financial year 2020:
In thousands of euros | KPMG | Naolys | TOTAL | |||||||||
Audit of accounts | 393 | 36 | 429 | |||||||||
Other services than auditing | 75 | — | 75 | |||||||||
|
|
|
|
|
| |||||||
TOTAL | 468 | 36 | 504 | |||||||||
|
|
|
|
|
|
Financial year 2021:
In thousands of euros | KPMG | Naolys | TOTAL | |||||||||
Audit of accounts | 367 | 36 | 402 | |||||||||
Other services than auditing | 97 | — | 97 | |||||||||
|
|
|
|
|
| |||||||
TOTAL | 464 | 36 | 500 | |||||||||
|
|
|
|
|
|
48